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ABSTRACT




B.S., IOWA STATE UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Leili Shahriyari
Cancer is a complex disease where every tumor has its own characteristics, and
thus different tumors may respond differently to the same treatments. Osteosar-
coma, which is a rare type of cancer with poor prognosis, is especially characterized
by its high heteogeneity. Therefore, it is important to study the progression of os-
teosarcoma tumors in different groups of patients with distinct characteristics. The
immune system has been reported to play an important role in the development of
various cancers with some immune cells having anti-tumor effects and others having
pro-tumor effects. With recent advances in digital cytometry methods, which are
techniques to estimate the fractions of various cell types from gene expression data
of a bulk of cells, it became possible to obtain relative abundance of immune cells
in tumors.
vi
In this project, we review common digital cytometry methods, compare their
performances and report the best method. We apply this best performing digital
cytometry method to estimate abundance of immune cells in osteosarcoma tu-
mors, and perform clustering using the estimated immune fractions to find groups
of tumors with distinct immune compositions. We then model the growth of os-
teosarcoma tumors in each group while taking into account the interactions be-
tween immune cells and cancer cells. Lastly, we investigate the effects of adding
chemotherapy on the progression of osteosarcoma, find the optimal chemotherapy
dosages for tumors in each cluster, and compare the behaviors of immune and can-
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C H A P T E R 1
INTRODUCTION
Cancer is the name for a group of diseases in which cells begin to grow uncon-
trollably. Every patient’s tumor develops and progresses in its own unique way,
and different tumors can have different sensitivities to cancer therapies [2]. The
variations between tumors, called inter-tumor heterogeneity, have become an im-
portant task to be studied by researchers in order to provide more individualized
and more effective treatments to cancer patients.
Several studies have shown that cancer cells and tumor infiltrating immune
cells play a key role in tumor progression and the identification of malignant tumor
types [3, 4, 5]. Innate immune cells contribute to tumor suppression in several
ways, such as recognition and killing of cancer cells [6]. The immune response
in the cancer microenvironment can be triggered by tumor antigen detection by
immature dendritic cells, which then mature into dendritic cells [7]. Dendritic cells
present these antigens to helper and cytotoxic T cells, resulting in their activation
and the direct killing of cancer by cytotoxic cells [8, 9, 10]. Helper T cells and
cytotoxic T cells also produce IFN-γ that inhibits tumor growth [10, 11, 12].
On the other hand, certain immune cells have promoting or dual effects on
cancer progression. Regulatory T cells inhibit the differentiation and activities of
helper and cytotoxic T cells, thus, indirectly promoting tumor by suppressing the
1
immune response [9, 13, 12, 14]. Macrophages, the most abundant immune cells
in many cancers, have anti-tumor properties by activating helper and cytotoxic
T cells through IL-12 and IL-23 production [15, 12, 16, 9], and also have pro-
tumor properties through secreting IL-6, which supports cancer cells’ proliferation
[15, 17, 18, 19, 20].
Moreover, the immune system is one of the major players in the response to
various cancer therapies [21, 22, 23], as it can improve or inhibit treatment effective-
ness and tumor behaviors [24]. For example, the necrotic cell death of tumor cells
caused by radiotherapy or chemotherapy triggers the production of high mobility
group box 1 (HMGB1), which is a damage-associated molecular pattern (DAMP)
molecule, and thus can induce immune responses [25, 26, 27, 28]. HMGB1 can pro-
mote dendritic cell maturation from naive dendritic cells [29, 30, 31, 32], leading
to the activation of T cells and elimination of cancer cells. Meanwhile, most can-
cer therapies also kill immune cells, where immune cells have complex interactions
with cancer cells, so the death of immune cells can have an indirect impact on the
growth of tumor.
Since cancer is a heterogeneous disease with numerous components, such as
immune cells, cancer cells, and lymphatic vessels [33], it is important take these
various components of cancer into consideration while studying the tumor pro-
gression. However, in typical in vitro and in vivo studies, cancer mechanisms or
components are usually analyzed one by one. While these experimental studies
provide relevant insights about the mechanisms, none of them can provide the ad-
equate required information to understand the complexity of cancer [34]. On the
other hand, mathematical modeling allows us to investigate multiple components
of a tumor at the same time. Thus, we can utilize mathematical models to combine
our knowledge on the individual cancer components and study the heterogeneity
2
of cancer.
Mathematical models are commonly used to examine the growth of tumors, to
identify the optimal combination of treatments, to improve responses to therapies,
and to combat drug resistance in various types of cancer [35, 36, 37, 38, 39, 40,
41, 42, 43, 44, 45]. Among those, several studies model the interactions of immune
cells and cancer cells; however, most of them only study one or two immune cells in
their framework [46, 47, 48, 49, 50, 51, 52, 53]. A study by Wilkie et al. modeled
the combination of all immune cells as one variable and analyzed its effects on
tumor growth [54]. However, the impacts of the immune system on cancer are
diverse with some immune cells having anti-tumor effects while others had pro-
tumor effects, and thus modeling the whole immune system as one variable would
fail to capture these important interactions. Only a few papers explore multiple
immune cells [55, 56, 57], but even these models did not investigate the influence
of macrophages, which have been shown to be the most abundant cell type in the
tumor microenvironment of many cancers.
Malignant bone tumors are a rare type of cancers that arises in the bones.
Osteosarcoma is the most common type of malignant bone tumors with about
1000 new cases diagnosed each year in the United States [58]. It can affect people
of any age, but it is mostly occurred in the children aged 10 to 14 and in adults aged
65 and older [59, 60]. Osteosarcoma usually starts in the femur, the tibia and the
humerus, and less commonly the skull, the jaw or the pelvis [15]. There are some
factors such as gender, age, heritable syndromes and certain conditions such as Li-
Fraumeni syndrome, hereditary retinoblastoma, and Bloom and Werner syndromes
that affect the risk of osteosarcoma [61]. However, the cause of osteosarcomas is
still not clear [62]. The types of standard treatments for osteosarcoma include
surgery, chemotherapy, radiotherapy, and targeted therapy [63].
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Although neoadjuvant chemotherapy has improved the outcomes of osteosar-
coma, the overall survival of patients with metastatic tumors still remains in low
rate in the last three decades [64, 65, 66]. Immunotherapy and targeted therapy
have recently demonstrated significant results in the treatment of certain cancer
types [67, 68]. Although these are popular alternative treatments for osteosar-
coma, they are still ineffective for many patients [69]. Osteosarcoma tumors have
also been reported to be resistant to the radiotherapy [70, 71]. Due to the poor
prognosis of osteosarcoma, it would be beneficial to build mathematical models to
investigate the progression of osteosarcoma, study the effects of common treatments
on its growth, analyze the drug resistance, and explore new treatments’ options.
There are a limited number of mathematical models that study cells in the
bones or treatments for osteosarcoma. Some of these studies examine the growth
of osteoblasts and osteoclasts in vitro, in healthy tissues or in bone metastases
[72, 73, 74]. Osteoclasts are the cells that break down bones to initiate bone
remodelling, while osteoblasts are the cells that synthesize new bone, and are also
the cells of origin of osteosarcoma. Other studies focus on the pharmacokinetics of
chemotherapy drugs for the treatment of osteosarcoma, [75, 76, 77]. However, to the
best of our knowledge, there is currently no model that investigates the growth of
primary tumors in osteosarcoma. And since the immune system plays an important
role in cancer growth as mentioned above, we want to build a mathematical model
for osteosarcoma that takes into account the interactions between cancer cells and
immune cells.
The relationship between clinical outcome and immune abundance in osteosar-
coma has been reported in many studies. Cytotoxic T cells, known as the primary
receptor of immune response targeting ostersarcoma [10], have an important role in
the immunological responses of osteosarcoma patients [78]. Also, a high number of
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M1 macrophages in osteosaroma tumors has been associated with good prognosis
in many studies [79, 85, 86], and it has been reported that low-risk patients have a
high number of cytotoxic T cells and NK cells [80]. Moreover, certain chemother-
apy drug such as Cisplatin can increase the cancer killing capacity of cytotoxic T
cells [81, 82, 83, 84], so the effectiveness of the drug also depends on the number
of cytotoxic T cells in the tumor microenvironment. Therefore, in this project, we
will model osteosarcoma progression separately for patients with different immune
compositions.
In order to distinguish patients with different immune compositions, we first
need to obtain the relative immune abundance within the primary tumor of each
patient. Many experimental approaches such as single-cell analysis tools, including
immunohistochemistry, flow cytometry and mass cytometry, have been utilized to
document tumor immune infiltrates. However, these methods are expensive and
time-consuming [87], because they require laboratories, professionals and equip-
ment. Obtaining the gene expression levels of a bulk of cells has become easier and
cheaper thanks to new advances in high-throughput RNA-sequencing tools [88].
Therefore, several deconvolution methods (DMs) have been developed in recent
years to estimate the relative abundance of each cell type in a bulk of cells, such
as tumors, from their gene expression profiles. This process of digitally estimating
the distribution of cell types from bulk gene expression data has also been referred
to as digital cytometry [89].
We will use a digital cytometry method to estimate the relative number of each
immune cell in primary tumors. We then divide osteosarcoma patients into groups
based on their immune profiles and model osteosarcoma progression separately for
each group. The estimated immune abundance will also be used as inputs to our
model. The outline of this dissertation is as follows:
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• Chapter 2: We review common digital cytometry methods and report the
method with the best performance. The results of this chapter has been
published in Briefings in Bioinformatics [90].
• Chapter 3: Using the best performing digital cytometry method to estimate
immune abundance, we group osteosarcoma patients based on their immune
compositions and compare survival outcomes among these groups. The re-
sults of this chapter has been published in Mathematical Biosciences and
Engineering [91].
• Chapter 4: We build a mathematical model to study the progression of os-
teosarcoma tumors in each group and compare our findings to the results of
Chapter 3. The results of this chapter has been published in Cancers [92].
• Chapter 5: We extend the model given in Chapter 4 to include common
chemotherapy drugs for osteosarcoma and analyze the effects of chemotherapy
on the growth of osteosarcoma tumors. The results of this chapter has been
published in Cells [93].
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C H A P T E R 2
A REVIEW OF DIGITAL CYTOMETRY METHODS:
ESTIMATING THE RELATIVE ABUNDANCE OF CELL
TYPES IN A BULK OF CELLS
In order to build a mathematical model for osteosarcoma progression, we want
to apply a digital cytometry method to estimate immune abundance in osteosar-
coma tumors. The estimated abundance of immune cells in these tumors are then
used to divide tumors into groups and as inputs to the mathematical model. As
several digital cytometry methods have been recently developed, it is important to
evaluate and compare their performance in estimating fractions of cells from the
gene expression data of a bulk of cells, since the quality of the digital cytometry
method we use will affect the results of our mathematical model.
There are two main categories of digital cytometry methods: linear models and
ranked based models. In this chapter, we review five common digital cytometry
methods [90], including three linear models: DeconRNASeq [94], CIBERSORT [95],
and CIBERSORTx [89], and two rank-based models [96]: ssGSEA deconvolution





DeconRNASeq [94] stands for Deconvolution of RNA-Seq. This method treats
the deconvolution task as a linear regression model with constraints on the model
coefficients. This method assumes the total expression level of a gene in a sample
is the sum of all the expression levels of the given gene in all cells in the sample.
DeconRNASeq takes as input the gene expression profile of a sample tissue,
called mixture data, and a “signature matrix” where each column is a “typical”
gene expression of a cell type. The method outputs the fractions of each cell type
included in the signature matrix for the given sample. The general formula for this
model is given as:
y = Xβ. (2.1)
Here, y denotes the observed gene expression level vector of a sample (mixture
data), X denotes the signature matrix where each column is the gene expression
level of a specific cell type, and β is the vector of estimated proportions of cell
types.
DeconRNASeq finds the estimated proportions of cell types (β) by minimizing




βi = 1 and βi ≥ 0,∀i, (2.2)
where βi is the estimated proportion of cell i in the sample. By minimizing this
objective function, the linear regression model finds the coefficients that result in
the smallest sum of squared difference between the observed and the predicted
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expression levels in the sample. The constraints are designed to make sure that the
cell proportions are positive and add up to 1. The optimization procedure is done
using quadratic programming [99, 100, 101].
CIBERSORT
CIBERSORT [95] stands for Cell-type Identification By Estimating Relative
Subsets Of RNA Transcripts. Like DeconRNASeq, this method assumes the total
expression level of a gene in a sample is the sum of expression levels of that gene
in all the cells in that sample. CIBERSORT utilizes a machine learning technique
called Support Vector Regression (SVR) for estimating cell proportions. Unlike
linear regression, which tries to find the linear function that minimizes the sum of
squared error, SVR tolerates a margin of error ε and only tries to minimize the sum
of absolute error of data points that lie outside this margin of error. In particular,
CIBERSORT uses the ν-SVR algorithm for this task. The general formula for
CIBERSORT is the same as DeconRNASeq (Eq. (2.1)). Similar to DeconRNASeq,
CIBERSORT takes a mixture data and a signature matrix as input and returns
the model coefficient β as estimated fractions of each cell type in the sample.
The only difference between these two methods is their optimization procedure;















s.t. yi − ŷi ≤ ε + ξi and ŷi − yi ≤ ε + ξ∗i and ξi, ξ∗i ≥ 0. Here, ε is the margin of
error, and (ξi + ξ
∗
i ) is the absolute error of data points that lie outside margin of
error ε. ν is a model hyperparameter that gives an upper bound on the fraction
of training error and a lower bound on the fraction of support vectors. Thus, the
9
value of ν is between 0 and 1.
Since y is a linear combination of X (Eq. (2.1)), CIBERSORT uses a linear
kernel in ν-SVR. Unlike DeconRNASeq, CIBERSORT does not put any constraints
on the model coefficient β during optimization, and there is no guarantee that
elements of β will be non-negative and add up to 1. Thus, after the optimization
process, CIBERSORT sets any negative coefficients to 0 and then normalizes the
coefficients such that they sum to 1.
CIBERSORTx
Since the gene expression data sets can be collected through completely different
experimental settings with the use of different experimentation plans, platforms,
and methodologies, there are undesired batch effects in the gene expression val-
ues. These technical variations can in some cases be as large as the biological
variations between different cell types [102]. It has been shown that the Com-
Bat algorithm [103] can effectively remove these unwanted variations from bulk
RNA-Seq data[102]. Newman et al. introduced CIBERSORTx [89], which extends
CIBERSORT by adding batch correction using ComBat to address the possible
cross-platform variations in gene expression data sets. CIBERSORTx introduces
two strategies for batch correction: B-mode and S-mode.
CIBERSORTx B-mode
As in CIBERSORT, mixture data y is modeled as a linear combination of sig-
nature matrix X and cell fractions β.
y = Xβ.
The algorithm of CIBERSORTx B-mode is as follows:
10
1. Use CIBERSORT to obtain estimated fractions β̂ from mixture data y and
signature matrix X.
2. Create estimated mixture data ŷ, where ŷ = Xβ̂.
3. Use ComBat [103] to eliminate the cross-platform variation between y and ŷ,
producing adjusted mixture data yadj.
4. Use CIBERSORT to estimate final cell fractions β from yadj and X.
CIBERSORTx S-mode
When the technical variation between signature matrix and mixture data is more
severe, Newman et al. [89] recommend to use S-mode, which adjusts the signature
matrix instead of mixture data. As input, S-mode requires the mixture data y and
the set of single-cell reference profiles R from which the signature matrix X was
derived. R consists of single-cell transcriptomes from different cell types, typically
multiple transcriptomes per cell type. The gene expression profile of each cell type
in X is constructed by aggregating the corresponding single-cell transcriptomes in
R. CIBERSORTx S-mode estimates cell fractions in the following way:
1. Let µ = [µ1, ..., µc] be the fractions of each cell type from X in R and σ = 2µ.
2. Generate artificial cell fractions β∗ by drawing from normal distributionNormal(µ, σ).
3. Set negative values of β∗ to 0 and normalize β∗ so its components sum to 1.
4. Sample single-cell transcriptomes from R according to β∗ and add them to-
gether to create artificial mixture data y∗.
5. Use ComBat [103] to eliminate the cross-platform variation between y and




6. Use non-negative least squares to find Xadj that minimizes (y
∗
adj −Xadjβ∗)2
such that Xadjij ≥ 0 for all i, j.
7. Use CIBERSORT to estimate final cell fractions β from original y and Xadj.
2.1.2 Rank-based models
ssGSEA DM
All above-mentioned linear models rely on a signature matrix to deconvolve
a bulk of cells using its gene expression profile. However, obtaining an accurate
signature matrix is very challenging in practice, because factors such as variations in
experimental settings and laboratory measurements can bias the signature matrix
[104]. Fortunately, the most highly expressed genes for any given cell type are
usually consistent across different laboratories and conditions. The deconvolution
method based on single sample gene set enrichment analysis (ssGSEA) only uses
these highly expressed genes of each cell type, here called cell signatures or up-
regulated gene sets, instead of a signature matrix.
The ssGSEA method [104], which is a modification of gene set enrichment anal-
ysis (GSEA) [105], was developed in order to get an enrichment score for a single
sample instead of two groups of samples. Here, we call the method developed by
Senbabaoglu et al. [97], which utilizes the ssGSEA score specifically for the digital
cytometry task, ssGSEA DM. This method takes mixture data and sets of highly
expressed genes for each cell type as input, and returns the enrichment score for
each cell type. The algorithm of ssGSEA DM is as follows:
1. Order mixture data by absolute expression from highest to lowest.
2. Replace gene expression values in mixture data by their ranks.
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3. For each gene i, in the ordered rank data from step 2, compute the following:













where G is the given cell signature, containing NG up-regulated genes, y is
the mixture data, containing N genes, rj is the rank of a gene j, and α is a
parameter in (0, 1].




[PwG (G, y, i)− PNG(G, y, i)] . (2.6)
The enrichment score of the cell signature G tells us the relative fraction of the
cell type with cell signature G. For example, assume T-cells and B-cells respectively
have the cell signatures G1 and G2. If the enrichment score of the cell signature
G1 is higher than the enrichment score of the cell signature G2, we conclude that
the number of T-cells is higher than the number of B-cells in the mixture data.
SingScore DM
SingScore [98] stands for single sample scoring of molecular phenotypes. Similar
to ssGSEA DM, SingScore DM uses enriched gene sets instead of a signature matrix
for performing digital cytometry. While ssGSEA DM only uses a set of up-regulated
genes for each cell type, SingScore DM has the option to use both up-regulated and
down-regulated gene sets for each cell type. Thus, SingScore DM takes as input
a set of up-regulated genes and an optional set of down-regulated genes for each
cell type along with the mixture data, and outputs a score for each cell type. The
algorithm of SingScore DM is as follows:
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1. Order mixture data by gene expression levels from highest to lowest.
2. Use the top half of genes in the sample as the up-set and the bottom half as
the down-set. An important remark is that these up-set and down-set genes
of the sample are different from the up-regulated and down-regulated gene
sets of each cell type.
3. Rank these genes in ascending order for up-set and descending order for down-
set.
4. For a given cell type and its up-regulated gene set Gup and down-regulated








where dir is the gene set direction (up-/down-regulated), Sdir,i is the score
for sample i against the directed gene set, Rgdir,i is the rank of gene g in the
directed set from the sample (up-set or down-set), Ndir,i is the number of
genes in Gdir that are observed within the mixture data.











6. Calculate output score for sample i:
S̄total,i = S̄up,i + S̄down,i (2.9)
Similar to ssGSEA DM, the output scores of SingScore DM algorithm are the
relative levels of each cell type in the sample, rather than the actual fractions.
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2.2 Approach
To compare the performance of the above-mentioned methods on the deconvo-
lution task, we generate simulation data with known mixing fractions and signal to
noise ratio (SNR) ranging from 100:5 to 100:50 (n = 100 samples for each SNR). We
use two different signature matrices: LM22 [95] and LM6 [106] for DeconRNASeq,
CIBERSORT, and CIBERSORTx. LM22 is derived from microarray data and con-
sists of 547 gene expressions for twenty-two leukocytes, while LM6 is derived from
RNA-Seq data and has 684 gene expressions for six leukocytes. These signature
matrices are also used to derive the up-regulated gene sets used for ssGSEA DM
and SingScore DM. We note that the single-cell reference profiles needed to run
CIBERSORTx S-mode are not available for the LM6 signature matrix, hence this
method is excluded from the LM6 results.
We construct the simulation data in the following manner: first, “known”
mixing fractions for a sample are obtained by drawing random numbers from
Uniform(0, 1) and then normalized so that the fractions in a sample sum to 1.
Mixture data is then formed by a linear combination of the LM22 source gene
expression profile and the known mixing fractions, where LM22 source gene ex-
pression profile is the gene expression profile used to create LM22, before the gene
selection step. Noise is induced to the simulation data by adding values drawn
from Normal(0, k
100
· σ), where σ is the global standard deviation of the original
simulation data without noise, and k is an integer. This results in a SNR ratio of
100:k for a given value of k. We create ten sets of simulated data with k chosen
from 5 to 50, in steady increments of 5, resulting in SNR ratios ranging from 100:5
to 100:50.
It is conceivable to encounter mixture data that consists of more cell types than
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those available in the signature matrix. To test for each method’s robustness to
this phenomenon, we delete a few cell types in the signature matrix LM22 and
run all five methods using the simulated mixture data with two signature matrices:
reduced LM22 and the original LM6.
We also apply these methods on two experimental data sets: whole blood RNA-
Seq data with ground truth cell fractions estimated by flow cytometry (n = 12)
(available on Gene Expression Omnibus under the accession number GSE127813
[89]), and PBMC microarray data with ground truth fractions estimated by flow
cytometry (n = 20) (available on Gene Expression Omnibus under the accession
number GSE65133 [95]). Although these data sets come from different platforms,
we cannot make any conclusive statements that these methods perform better on
RNA-Seq vs microarray data due to the limited availability of data sets with ground
truth fractions. For each experimental data set, we run all five methods with the
original LM22 and the original LM6.
To facilitate a fair comparison of the performance of the five deconvolution
methods, we want the signature matrix used in linear methods to come from the
same database as the gene sets used in rank-based methods. Thus, we use the data
sources of LM22 to create up-regulated gene sets for ssGSEA DM and SingScore
DM by applying a method similar to [107]. First, we separate the samples in the
single cell reference profiles of LM22 into groups according to their cell type. For
each gene, we calculate the difference between the minimum expression in the group
of interest and the highest mean expression of all other groups. If this difference
is greater than a threshold, we select this gene as an up-regulated gene for the
cell type of the analyzed group. We do this for every group to select the highly
expressed genes in each cell type specific group. We apply the same technique to
derive up-regulated gene sets from LM6. However, since we do not have access to
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the reference profiles of LM6, we apply this technique on LM6 itself. These gene
sets derived from LM22 and LM6 are available for download on our GitHub page
(see section 2.5).
We ran the above digital cytometry methods using the following software:
• DeconRNASeq package in R for DeconRNASeq,
• CIBERSORT’s R source code for CIBERSORT,
• CIBERSORTx’s website application for CIBERSORTx,
• gsva package in R for ssGSEA DM,
• SingScore package in R for SingScore.
Each of these methods have their own form of normalization in their algorithm.
In ssGSEA DM and SingScore DM, the normalization is not applied on the input
mixture data, and since input gene sets are only lists of gene names, no normal-
ization can be applied here either. The only normalization in rank-based methods
is applied on output scores at the end of the algorithm, thus making output scores
nicer for visualization without changing the correlation of the predicted values with
the ground truth fractions. On the other hand, CIBERSORT and CIBERSORTx
use z-score normalization on their inputs (the signature matrix and mixture data)
as a mandatory initial step in their software, and DeconRNASeq software pro-
vides an option to first standardize the input mixture data. The results of these
linear models with normalization will differ from those without. CIBERSORT
and CIBERSORTx also have optional quantile normalization on the input mix-
ture data. This quantile normalization is recommended for microarray data but
not for RNA-Seq data. Since the PBMC microarray data set has been previously
normalized with the limma package in R, using ‘normexp’ background correction
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with negative controls [95], and the whole blood data set is RNA-Seq data, we use
CIBERSORT and CIBERSORTx without quantile normalization in this study. For
DeconRNASeq, ssGSEA DM and SingScore DM, we use normalization (which is
the default setting for these methods).
We note that since rank-based methods output relative scores as opposed to
frequencies, we cannot use traditional metrics such as mean square error to compare
the performance of each method to the original data. Thus, we instead consider
four different measures of correlation: Pearson correlation per sample, Pearson
correlation per cell, Spearman correlation per sample, and Spearman correlation
per cell. Correlation per sample between estimated and true fractions tells us how
well a method estimates the relative frequency of all cell types in a given sample,
while correlation per cell tells us how well a method estimates the relative frequency
of a given cell type between all samples.
2.3 Results
2.3.1 Analysis of simulation data
We create simulation data as described in the Approach section, and apply each
of the above-mentioned methods with both the reduced LM22 and the original LM6
signature matrices (or corresponding derived gene sets for rank-based methods).
For all methods and signature matrices, the Pearson and Spearman correlation
results are consistent with one another. With reduced LM22, the more noise is
added to the data set, the lower the correlations observed between the ground truth
fractions and the methods’ predictions, with the following exceptions: the sample-




Figure 2.1. Results on simulation data with different SNR from 100:5
to 100:50. Note in A and B, the ssGSEA results align with
SingScore. A-D: mean correlation between flow cytometry cell frac-
tions and predicted cell fractions obtained from running methods
with reduced LM22, across different noise levels. A: sample-level
Pearson correlation, B: sample-level Spearman correlation, C: cell-
level Pearson correlation, D: cell-level Spearman correlation. F-I:
mean correlation between flow cytometry cell fractions and pre-
dicted cell fractions obtained from running methods with LM6,
across different noise levels. F: sample-level Pearson correlation,
G: sample-level Spearman correlation, H: cell-level Pearson corre-
lation, I: cell-level Spearman correlation.
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much when the signal to noise changes (Figure 2.1A,B). For LM22, CIBERSORT
and CIBERSORTx B-mode perform best on data with high signal to noise. The
batch correction in CIBERSORTx does not appear to improve the method for this
simulated data, however we note that the simulated data and signature matrix are
both derived from LM22, and therefore there should not be any cross platform
variation to eliminate. Interestingly, DeconRNASeq with reduced LM22 performs
just as well as CIBERSORT and CIBERSORTx when the noise level is high.
For all methods with LM6, cell-level correlations with true fractions again de-
crease as noise increases, but sample-level correlations stay roughly the same across
all noise levels (Figure 2.1E-H). The insensitivity to the noise levels of sample-
level results with LM6 could be due to the fact that simulation data was cre-
ated using LM22 source gene expression profile instead of LM6. When LM6 is
used, CIBERSORT and CIBERSORTx B-mode again perform the best per sam-
ple, although correlations are lower than with reduced LM22. Figure 2.1E,F shows
that CIBERSORTx B-mode outperforms CIBERSORT with LM6, suggesting that
CIBERSORTx B-mode is better than CIBERSORT when the signature matrix and
mixture data are from different platforms. Interestingly, DeconRNASeq with LM6
performs worst per sample (Figure 2.1 E,F), but best per cell (Figure 2.1G,H). The
poor performance per sample of DeconRNASeq with LM6, but strong performance
with LM22, may indicate DeconRNASeq’s lack of robustness when signature ma-
trix comes from a different platform than mixture data. It is worth noting that
the rank-based methods perform poorly across all noise levels with both signa-
ture matrices. In particular, rank-based methods produce very low sample-level
correlations with ground truth fractions (Figure 2.1A-B,E-F).
In addition to examining the mean correlations, we created box plots of the
100 different sample-level correlations, and the sixteen (LM22) or six (LM6) dif-
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Figure 2.2. Results on simulation data with SNR 100:10. A-D: box
plots of correlations between ground truth cell fractions and pre-
dicted cell fractions obtained from running methods with LM22. A:
sample-level Pearson correlation, B: sample-level Spearman corre-
lation, C: cell-level Pearson correlation, D: cell-level Spearman cor-
relation. F-I: box plots of correlations between ground truth cell
fractions and predicted cell fractions obtained from running meth-
ods with LM6. F: sample-level Pearson correlation, G: sample-level
Spearman correlation, H: cell-level Pearson correlation, I: cell-level
Spearman correlation.
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ferent cell-level correlations, using the simulation data generated with SNR 100:10
(Figure 2.2). We observe in Figure 2.2A-B,E-F that the variances in sample-level
correlations, particularly with LM6, are quite large for all methods. The cell-level
correlation plots (Figure 2.2C-D) show that while CIBERSORT and CIBERSORTx
with LM22 produce results that are highly correlated (r > .75) with the ground
truth for all individual cell types besides CD4 memory resting T-cells, the other
methods show a larger variation in performance among the different cell types. In
particular, we note that DeconRNASeq does a poor job predicting the number of
resting NK cells, bringing down the method’s mean correlation per cell with LM22.
However this observation does not hold when LM6 is used. This may help explain
the discrepancy in DeconRNASeq’s performance in mean cell-level correlation with
LM22 and LM6. With LM6, all methods besides DeconRNASeq do a poor job
predicting the relative number of CD4 T Cells, but do a great job predicting the
relative level of Neutrophils.
2.3.2 Analysis of whole blood data
We obtain the ground truth fractions of neutrophils, lymphocytes, monocytes,
T-cells, CD8+ T-cells, CD4+ T-cells, B-cells, and NK cells for whole blood data
(GSE127813) from CIBERSORTx [89] and compare them with the corresponding
estimated fractions obtained using the above-mentioned methods. Since LM22
has twenty-two leukocytes, we sum the estimated fractions of certain cell sub-
types to match them with the ground truth cell types. For example, we sum the
estimated fractions of CD4+ naive T-cells, CD4+ memory resting T-cells, and
CD4+ memory activated T-cells to compare it with the ground truth fraction of
CD4+ T-cells. However, there are still eight leukocytes that do not have a similar
match to the categories of the ground truth cells, and so we exclude them from our
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analysis. These cell types are macrophages (M0, M1, M2), dendritic cells (resting,
activated), mast cells (resting, activated), and eosinophils. Hence we do not expect
estimated percentages to sum precisely to 1. A similar procedure is applied to
the results obtained with LM6, and we end up comparing estimated fractions and
ground truth fractions in neutrophils, monocytes, T-cells, CD8+ T-cells, CD4+
T-cells, B-cells and NK cells.
In agreement with the simulation data results, the linear methods perform better
in overall than the rank-based methods in terms of correlation per sample (Figure
2.3A-B,F-G). Of all the methods, CIBERSORT and CIBERSORTx B-mode again
perform best per sample, both with LM22 and LM6, while CIBERSORTx S-mode
performs worse than these two. DeconRNASeq performs much better in terms of
Pearson correlation (and slightly better in terms of Spearman correlation) with the
use of LM22 than with LM6. On the other hand, ssGSEA DM and SingScore DM
perform very poorly with gene sets from LM22 (Figure 2.3A-B), but do a better
job with gene sets from LM6 (Figure 2.3F-G). We should note that sample-level
Pearson correlations of ssGSEA DM and SingScore DM are low for both gene sets,
but since Pearson correlation is not a good measure for rank-based results, we
should focus on Spearman correlation when analyzing the performance of these
two methods.
With regards to correlation per cell, CIBERSORT and CIBERSORTx B-mode
perform the best with LM22 (Figure 2.3C-D). In contrast to the simulation data re-
sults, rank-based methods perform best with LM6 (Figure 2.3H,I), though CIBER-
SORT and CIBERSORTx B-mode are not far behind. DeconRNASeq performs
the worst out of all methods with LM6, but still achieves cell-level Pearson and
Spearman correlations > 0.6. CIBERSORTx S-mode performs very well, but still
worse than original CIBERSORT and CIBERSORTx B-mode. In particular, all
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Figure 2.3. Results on whole blood data. A-D: box plots of correlations
between flow cytometry cell fractions and predicted cell fractions
obtained from running methods with LM22. A: sample-level Pear-
son correlation, B: sample-level Spearman correlation, C: cell-level
Pearson correlation, D: cell-level Spearman correlation. E: stacked
bar charts of predicted cell fractions by each method with LM22
and ground truth flow cytometry cell fractions. F-I: box plots
of correlations between flow cytometry cell fractions and predicted
cell fractions obtained from running methods with LM6. F: sample-
level Pearson correlation, G: sample-level Spearman correlation, H:
cell-level Pearson correlation, I: cell-level Spearman correlation. J:
stacked bar charts of predicted cell fractions by each method with
LM6 and ground truth flow cytometry cell fractions.
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linear methods do a somewhat poor job predicting NK cells, compared to other cell
types, and rank-based methods do a poor job at predicting monocytes.
Overall, CIBERSORT and CIBERSORTx give the best results for the whole
blood data set (Figure 2.3). Among CIBERSORT models, CIBERSORTx S-mode
performs poorly, but still gives relatively good results in terms of Spearman cor-
relation with ground truth fractions (Figure 2.3 B,D). The comparison between
Figure 2.3A and Figure 2.3F shows that DeconRNASeq results are very different
between LM22 and LM6, suggesting that DeconRNASeq is very sensitive to the
signature matrix. In combination with the analysis of DeconRNASeq in simulation
data, this result indicates that DeconRNASeq’s performance is highly dependent
on the compatibility between signature matrix and mixture data.
Lastly, we compare the cellular profiles generated by each method to the ground
truth fractions in Figure 2.3E,J. Since ssGSEA DM and SingScore DM return
enrichment scores instead of estimated fractions, the total sum of the output scores
for each sample does not need to be less than or equal to 1. As mentioned earlier,
since they are rank-based, we should not expect them to produce scores close to
ground truth fractions, but rather hope to see their output scores consistent with
the ranks of true fractions (i.e. if neutrophil have the highest number in the ground
truth data, we would expect these methods to give neutrophils the highest score
among all cell types). However, ssGSEA DM and SingScore DM estimate similar
scores of cell types for different samples, even though ground truth fractions differ
across samples (Figure 2.3E,J). Linear methods, on the other hand, are able to
capture the difference in distribution of fractions across samples. Although fractions
estimated by CIBERSORT and CIBERSORTx do not completely match the ground
truth fractions, these methods do succeed in capturing important patterns such
as the relative levels of neutrophils, T-cells, B-cells, and NK cells in samples. All
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methods overestimate the fraction of B-cells, and all but DeconRNASeq with LM22
drastically underestimate the fraction of neutrophils (Figure 2.3E). The two rank-
based methods, ssGSEA DM and SingScore DM, produce similar output scores to
each other. CIBERSORT and CIBERSORTx are expected to give similar estimated
fractions since they both use ν-SVR and the only difference is that CIBERSORTx
uses batch-correction before applying ν-SVR. We observe a slight improvement in
performance with CIBERSORTx compared to CIBERSORT for this data set.
2.3.3 Analysis of PBMC data
PBMC data, (GSE65133) [95], includes flow cytometry fractions for naive B-
cells, memory B-cells, CD8+ T-cells, CD4+ naive T-cells, CD4+ memory resting
T-cells, CD4+ memory activated T-cells, γδ T-cells, NK cells, and monocytes. Fol-
lowing the same procedure as mentioned before, we compare the estimated fractions
to flow cytometry fractions of naive B-cells, memory B-cells, CD8+ T-cells, CD4+
naive T-cells , CD4+ memory resting T-cells, CD4+ memory activated T-cells,
γδ T-cells, NK cells and Monocytes for LM22, and B-cells, CD8+ T-cells, CD4+
T-cells, NK cells, and Monocytes for LM6.
We repeat the correlation analysis with the PBMC data set, and the sample-
level results are somewhat different from our findings from the whole blood data set.
In general, the rank-based methods perform much better in terms of correlation per
sample on the PBMC data than on the other two data sets, while DeconRNASeq
performs considerably worse. With LM6, sample-level Spearman correlations show
high variance across samples for all methods (Figure 2.4F-G). This implies that
all methods have an inconsistent behaviour; i.e. for some samples they perform
better than other samples. However, it is worth noting that there are only five
cell types overlapping between LM6 cell types and ground truth cell types. The
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sample-level correlation across only five cell types is susceptible to being low when
only one or two cell types are poorly predicted, and as seen in Figure 2.4H-I, these
methods do a poor job estimating the relative frequency of B-cells with LM6. In
fact, we also observe high variance in LM6 sample-level results on the simulation
data (Figure 2.2G), where the number of cell types (six) is small as well and the
poor estimation of CD4 T-cells likely contributes to some samples having low corre-
lation with true fractions with all methods. Overall, CIBERSORT, CIBERSORTx
B-mode, ssGSEA DM and SingScore DM perform better per sample than Decon-
RNASeq and CIBERSORTx S-mode with LM22 (Figure 2.4A,B), and Figure 2.4
F,G indicates no significant differences in performance between linear models and
rank-based methods with LM6.
With regards to cell-level correlation, CIBERSORT and CIBERSORTx B-mode
again perform best with the LM22 signature matrix, while the rank-based methods
perform considerably worse compared to the whole blood and simulation data (Fig-
ure 2.4C,D,H,I). However, when LM6 is used, the rank-based methods outperform
the linear models (Figure 2.4H-I). All methods except DeconRNASeq with LM22
signature matrix do well on predicting the number of CD8+ T-cells and Mono-
cytes. Additionally, all methods but DeconRNASeq with LM6, ssGSEA DM and
SingScore DM with LM22 show high correlations with the ground truth for NK
cells. CIBERSORT and CIBERSORTx B-mode with LM22 signature matrix are
the only methods for which the majority of cell types have correlation coefficients
r > 0.5. However, even these methods struggle to accurately predict the number of
CD4+ memory resting T-cells and γδ T-cells with LM22 (Figure 2.4C-D), as well
as the number of B-cells when using LM6 (Figure 2.4H-I).
Similar to the whole blood data set, we also plot the predicted cellular profiles
estimated by the methods in a stacked bar chart, along with the ground truth
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Figure 2.4. Results on PBMC data. A-D: box plots of correlations between
flow cytometry cell fractions and predicted cell fractions obtained
from running methods with LM22. A: sample-level Pearson cor-
relation, B: sample-level Spearman correlation, C: cell-level Pear-
son correlation, D: cell-level Spearman correlation. E: stacked bar
charts of predicted cell fractions by each method with LM22 and
ground truth flow cytometry cell fractions. F-I: box plots of cor-
relations between flow cytometry cell fractions and predicted cell
fractions obtained from running methods with LM6. F: sample-
level Pearson correlation, G: sample-level Spearman correlation,
H: cell-level Pearson correlation, I: cell-level Spearman correlation.
J: stacked barcharts of predicted cell fractions by each method with
LM6 and ground truth flow cytometry cell fractions.
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fractions (Figure 2.4E,J). We again note that we have omitted cell types that were
present in the signature matrix but not in the PBMC data. Hence, we do not expect
the frequencies to necessarily sum to 1. The rank-based methods do a slightly better
job at capturing variations among samples in this data set as compared to the whole
blood data. However, the CIBERSORT methods, particularly CIBERSORTx B-
mode, again exhibit the best overall performance.
2.4 Discussion
As mentioned in the Approach section, the normalization in linear methods can
affect their performance on the deconvolution of bulk gene expression data. Unlike
CIBERSORT and CIBERSORTx, DeconRNASeq does not have clear guidance on
whether to use its normalization and when to use it. We tried DeconRNASeq both
with and without normalization on our data sets. DeconRNASeq with normaliza-
tion gives overall better results in the whole blood and PBMC data sets, and gives
similar results to without normalization in simulation data. However, we would
like to note that just because DeconRNASeq with normalization works better on
these specific data sets does not mean it would work better on other data sets as
well. One positive aspect of the linear methods’ normalization is that it helps these
algorithms converge faster and easier, which reduces the run time significantly.
We provide a comparison of each of these methods’ run time per sample in
Table 2.4. Run time for each of the three data sets was calculated as the average
of twenty runs, using a 2.5 GHz Intel Core i7 CPU with 16 GB of RAM, and
then normalized by the number of samples in the data set. All methods besides
CIBERSORTx were run in R. We note that the CIBERSORTx team provides a web
portal to run their software, removing any dependencies on hardware or software.
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Table 2.1: Method Runtimes per Sample (mean +/- stan-
dard deviation, in milliseconds)
Data set Method Runtime Runtime
with LM22 with LM6
DeconRNASeq 53.11± 1.93 41.23± 0.81
Wholeblood CIBERSORT 325.23± 15.11 181.84± 8.11
(58,581 genes/sample) ssGSEA 1296.12± 53.3 293.59± 13.85
SingScore 13.93± 0.49 7.04± 0.35
DeconRNASeq 21.65± 0.54 18.86± 0.55
PBMC CIBERSORT 354.68± 16.29 109.9± 5.67
(34,694 genes/sample) ssGSEA 115.7± 4.72 73.81± 2.91
SingScore 6.36± 0.24 1.66± 0.11
DeconRNASeq 12.87± 0.14 11.97± 0.09
Simulation CIBERSORT 158.79± 9.09 80.73± 4.66
(11,845 genes/sample) ssGSEA 64.24± 1.33 39.91± 0.66
SingScore 1.39± 0.02 1.27± 0.01
Therefore it would not be a fair comparison to include this method in Table 2.4.
While the original CIBERSORT also has a web portal to run the method, we
used the CIBERSORT R source code to record time-to-compute, while making
sure that the results from the R code are identical to those from the web portal.
We note that CIBERSORTx takes longer than CIBERSORT, since the method
runs batch correction before applying CIBERSORT. SingScore is the fastest of
the five methods, followed by DeconRNASeq, while ssGSEA and CIBERSORT
are significantly slower. Unsurprisingly, all methods run faster with the smaller
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LM6 signature matrix than with LM22. In general, the run time per sample also
decreases for data sets with a smaller number of genes per sample.
As discussed in the Results section, rank-based methods tend to estimate very
similar scores across samples, while linear models are able to capture some vari-
ations in fractions among samples (Figure 2.3E,J and Figure 2.4E,J). Since rank-
based methods use the rank of the genes instead of the actual expression value in
the calculation of output score, as long as the genes have the same ranks across
samples, ssGSEA DM and SingScore DM will output the same scores across sam-
ples (even when these genes have very different expression values across samples).
Thus, rank-based methods can still successfully estimate the ranks of frequencies
between cell types, but might fail to estimate the relative frequencies of a given cell
type in samples. This is, in fact, the main disadvantage of rank-based methods,
as mentioned in Table 2.4 where we discuss the advantages and disadvantages of
each digital cytometry method. There has been a novel attempt, introduced by
Aran D. et al [108], to transform enrichment scores to make them more comparable
with cell fractions. These transformed enrichment scores are intended to be more
on the same range with cell fractions, but are not designed to be used in place of
cell fractions. Converting enrichment scores to cell fractions is generally a hard
problem, since enrichment scores are derived using only ranks of the genes instead
of gene expression values themselves.
Table 2.2: Advantages and disadvantages of methods
Methods Advantages Disadvantages
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DeconRNASeq • Outputs are cell fractions
• Open source implementations
available in Python and R
• Quick run-time
• Requires a signature matrix
as an input
• Performance is highly de-
pendent on the compatibil-
ity between signature ma-
trix and mixture data
CIBERSORT • Outputs are cell fractions
• Open source implementations
available in Python and R
• Web portal available for run-
ning method
• Good performance on digital
cytometry task





• Outputs are cell fractions
• Web portal available for run-
ning method
• Good performance on digital
cytometry task
• Eliminates the batch effect be-
tween signature matrix and
mixture data by adjusting
mixture data





• Outputs are cell fractions
• Web portal available for run-
ning method
• Eliminates the batch effect be-
tween signature matrix and
mixture data by adjusting sig-
nature matrix
• Requires a signature matrix
as an input
• Does not perform as well as
CIBERSORTx B-mode
ssGSEA DM • Does not require a signature
matrix; it only uses the up-
regulated gene sets of each cell
type
• Open source implementations
available in Python and R
• Outputs are scores for each
cell type rather than cell
fractions
• Produces similar scores for
samples with varying distri-
butions of cell types
• Slow run-time
SingScore DM • Does not require a signature
matrix; it can use both up-
regulated and down-regulated
gene sets of each cell type
• Open source implementations
available in Python and R
• Quick run-time
• Outputs are scores for each
cell type rather than cell
fractions
• Produces similar scores for
samples with varying distri-
butions of cell types
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The rank-based methods generally perform better in terms of all four corre-
lation metrics when the up-regulated gene sets came from the same platform as
the mixture data. In particular, for the microarray PBMC and simulation data,
ssGSEA DM and SingScore DM results have higher correlations with the ground
truth when using LM22 (derived from microarray data) compared to LM6 (derived
from RNA-Seq data). Similarly, for the RNASeq whole blood data, ssGSEA DM
and SingScore DM results are more correlated with ground truth fractions when
using LM6 compared to LM22.
We further note that the rank-based methods analyzed in this study were orig-
inally introduced for the task of analyzing the enrichment of a gene set in a single
sample, and have recently been adopted for the digital cytometry task. Enrich-
ment analysis refers to a group of methods for determining a set of enriched genes
either in a sample or between two groups of samples. There are three generations
of enrichment analysis methods: over-representation analysis, functional class sort-
ing techniques, and pathway topology-based techniques [96]. Both ssGSEA and
SingScore belong to the second generation, functional class sorting techniques. To
the best of our knowledge, among all enrichment analysis methods, only these two
single sample enrichment methods have been used for digital cytometry. It would
be worth exploring whether adopting other single sample enrichment methods for
digital cytometry would lead to better results.
In terms of linear methods, throughout this study, we have seen good perfor-
mance from both CIBERSORT and CIBERSORTx B-mode. Since CIBERSORTx
uses batch correction to account for cross-platform variation between the signature
matrix and mixture data, we should expect CIBERSORTx to perform at least as
well as CIBERSORT when signature matrix and mixture data come from differ-
ent platforms. Indeed, we see marginal improvements of CIBERSORTx B-mode
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over CIBERSORT in both PBMC and simulation data with LM6 (Figure 2.1E-H,
2.4F-I) where mixture data comes from microarray data and signature matrix comes
from RNA-Seq data, and qualitatively similar performance between CIBERSORTx
B-mode and CIBERSORT in whole blood data with LM22 (Figure 2.3A-D) where
mixture data comes from RNA-Seq data and signature matrix comes from microar-
ray data. In fact, CIBERSORTx B-mode slightly outperforms CIBERSORT in
both PBMC and whole blood experimental data sets regardless of signature matrix
used. However, CIBERSORTx B-mode underperforms CIBERSORT by a small
margin in the simulation data with LM22, raising the possibility that batch cor-
rection may negatively affect the performance of CIBERSORT if signature matrix
and mixture data come from the exact same platform.
Newman et al. [89] mention that CIBERSORTx B-mode should be used when
signature matrix is derived from bulk sorted reference profile or when the technical
variation between signature matrix and mixture data is moderate, while CIBER-
SORTx S-mode should be used when this variation is high. Figure 2.3A-D and
Figure 2.4A-D show that CIBERSORTx S-mode performs worse than both origi-
nal CIBERSORT and CIBERSORTx B-mode in both experimental data sets, sug-
gesting that the technical variation between LM22 and these data sets is not high.
These results also suggest that it is better to use CIBERSORTx B-mode than
CIBERSORTx S-mode when the technical variation between signature matrix and
mixture data is low. We would like to mention that many studies on tumor mi-
croenvironment have recently utilized digital cytometry methods, most commonly
CIBERSORT [109, 110, 111, 112, 113] and ssGSEA [114, 115, 116, 117], and two
separate studies on blood leukocyte and tumor infiltrating leukocytes enumera-
tion indicate that iSort, a transcriptome deconvolution method based on CIBER-




The PBMC data set and its flow cytometry fractions are available on the
CIBERSORT website at https://cibersort.stanford.edu under the name “Fig
3a PBMCs Gene Expression” and “Fig 3a PBMCs Flow Cytometry”, respectively.
The whole blood data set is available on Gene Expression Omnibus with identifier
GSE 127813, and its flow cytometry fractions are available on the CIBERSORTx
website at https://cibersortx.stanford.edu under the name “Ground truth
whole blood (txt)”. The simulation data created for this study, as well as the
up-regulated gene sets we derived from LM22 and LM6, can be found on our
github page. The data portion of our github repository is located at https://
github.com/ShahriyariLab/TumorDecon/tree/master/TumorDecon/data. The
simulation data and gene sets can be found under the names “Simulation data”,
“LM22 up genes.csv”, and “LM6 up genes.csv”, respectively.
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C H A P T E R 3
IMMUNE CLASSIFICATION OF OSTEOSARCOMA
As indicated in chapter 2, CIBERSORTx B-mode performs the best among
popular digital cytometry methods, especially when the mixture data and signature
matrix come from different platforms. In this chapter, we use CIBERSORTx B-
mode to investigate the immune patterns of osteosarcoma tumors and analyze the
relationship between immune composition and clinical features of osteosarcoma
patients [91].
There have been many other studies that utilize a deconvolution method to
study the tumor microenvironment of osteosarcoma. A number of them use the es-
timated immune infiltrations calculated using CIBERSORT and/or immune scores
calculated using ESTIMATE to find immune-related genes that can predict the
prognosis of osteosarcoma [85, 120, 121, 122]. Another set of studies find genes
with prognostic values by applying Cox model on survival data or performing dif-
ferentially expressed genes analysis between two groups of interest, and then in-
vestigate the relationship between these genes and estimated immune infiltrates
[80, 86, 123, 124, 125]. Others study the association of immune abundance with
clinical information directly [79, 121, 126, 127, 128]. Our work falls somewhat into
the third category.
Among the studies that directly investigate the relationship between immune
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infiltrations and clinical information, three of them use TARGET data set [79, 121,
127], one uses data from GSE21257 [126], and one uses data from GSE39058 [128].
Most of these studies use CIBERSORT [121, 127, 126, 128], while the other uses
ssGSEA and ImmuCellAI along with expression of immune marker genes to get es-
timated abundance of immune cells [79]. Our study, on the other hand, utilizes the
latest and best performing version of deconvolution methods called CIBERSORTx
B-mode, and conducts our analyses on both TARGET data set and GSE21257 data
set. We also perform K-means clustering using the estimated immune abundance
to study the clinical characteristics of different immune patterns in osteosarcoma.
Another study has used hierarchical clustering on immune abundance, but they es-
timate immune abundance using ssGSEA and do not focus on the clinical difference
between clusters [129].
3.1 Materials and methods
3.1.1 Data collection and processing
The gene expression data sets in this study are obtained from 2 cohorts: TAR-
GET (cohort 1) and GSE21257 (cohort 2). Cohort 1 includes FPKM normalized
RNA-seq data of 88 osetosarcoma patients downloaded from the UCSC Xena web
portal and their corresponding clinical data downloaded from the GDC data por-
tal. Cohort 2 includes microarray data and corresponding clinical features of 53
osteosarcoma samples, downloaded from GEO website. Cohort 2’s gene expres-
sion data were previously normalized with robust spline normalization before being
downloaded.
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3.1.2 Relative abundance of immune cells
We calculate the relative frequencies of 22 immune cell types by applying
CIBERSORTx [89] B-mode algorithm with immune signature matrix LM22 on
gene expression data from both cohort 1 and 2. The results in chapter 2 have
shown that CIBERSORTx B-mode gives good estimates of immune abundance in
both RNA-Seq and microarray data with the use of LM22, and in fact outperforms
CIBERSORT and other tumor deconvolution methods. We obtain estimated im-
mune fractions by running the algorithm on their website with 100 permutations.
Similar to CIBERSORT, CIBERSORTx outputs a p-value for each deconvolved
sample as an indicator of confidence of the results. We use samples with p-value
less than 0.05 for analyses in this chapter.
3.1.3 Identification of immune patterns in osteosarcoma
To calculate the abundance of each cell type, which has several subtypes with a
small abundance, we sum the proportions of their subtypes obtained from CIBER-
SORTx. The abundance of B cells is the summation of naive and memory B cells;
NK cell is the summation of resting and activated NK cells; Mast cells is the sum-
mation of resting and activated Mast cells; Dendritic cells is the summation of
resting and activated Dendritic cells; and CD4 T cells is the summation of follic-
ular helper T cells, regulatory T cells, naive CD4 T cells, resting and activated
memory CD4 T cells. We do not combine subtypes of Macrophages because M1
and M2 Macrophages have very different functions and Macrophages make up the
majority of immune cells in osteosarcoma.
We then use K-means clustering to identify various immune patterns of osteosar-
coma based on the estimated immune cells’ abundance. The number of clusters in
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K-means is determined using elbow method. A t-SNE visualization of the clusters
is also included to see how well K-means algorithm distinguishes between samples
with different immune patterns.
3.1.4 Immune scores of osteosarcoma tumors
Immune scores of all samples in cohort 1 and 2 are computed from ESTIMATE
algorithm [130]. In order to do so, we run estimate package locally from R. We also
divide all patients from both cohorts into low immune score and high immune score
group using the median immune score as cut-off to study the relationship between
immune score and survival outcome.
3.1.5 Statistical analysis
Chi-square test is used to analyze the relationship between categorical variables
in this study. We employ Mann-Whitney-Wilcoxon test to detect any significant
difference between groups of continuous variables, such as immune fractions, gene
expression, age and immune score. Pearson correlation and corresponding p-value
are used to study the correlation between different immune infiltrates.
To investigate the impact of immune infiltrates on survival, for each immune
cell, we split all patients into high and low abundance group using the median
value as cut-off and perform log-rank test to find significant difference in survival
between groups. Kaplan-Meier curves are also plotted to visualize the differences
between these groups.
All analyses in this study are conducted on all samples in both cohorts 1 and
2, except for metastasis-free survival analysis which is applied only on cohort 2
since cohort 1 does not include data on the time of metastasis development. All
statistical analyses and visualizations are carried out in Python.
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3.2 Results
3.2.1 The most abundant immune cells in osteosarcoma are Macrophages
and CD4 T cells
Results of CIBERSORTx B-mode on gene expression profiles of 141 osteosar-
coma patients (cohorts 1 and 2) demonstrates that M0 Macrophages is the most
frequent immune cell in osteosarcoma tumors with an average of 40% of total im-
mune cells, followed by M2 Macrophages and CD4 T cells (Figure 3.1B, C). Unsu-
pervised hierarchical clustering of immune cell fractions shows that most abundant
cells tend to be clustered together, as is shown in Figure 3.1A, where M0 and M2
Macrophages are clustered together and then grouped with CD4 T cells and other
immune cells. In addition, the most frequent cells also have the highest variation
in abundance across osteosarcoma tumors (Figure 3.1B).
3.2.2 Correlation between immune infiltrates in osteosarcoma
According to the CIBERSORTx B-mode results, abundance of CD8 T cells
is negatively correlated with M0 Macrophages and positively correlated with M1
Macrophages with Pearson correlation coefficients of −0.62 and 0.55, with p-values
of 4.8e−16 and 1.1e−12, respectively (Figure 3.1E). The proportion of γδ T cells
is also significantly negatively correlated with CD4 T cells and NK cells (Pearson
coefficients of −0.6 and −0.62, with p-values of 4.3e-15 and 1.8e-16). Interestingly,






Figure 3.1. Immune pattern of osteosarcoma. Sub-figure A shows the hi-
erarchical clustering of estimated immune cells’ infiltration. Sub-
figure B and C display the boxplot and stacked barchart of these
immune cells’ fractions. Sub-figures D shows the average frequen-
cies of immune cells in 3 clusters obtained from K-means cluster-
ing. Sub-figure E indicates the correlation map of immune cell
frequencies. Sub-figure F displays the boxplot of ESTIMATE im-
mune scores in 3 clusters, with asterisks indicating significant dif-
ference from Mann-Whitney-Wilcoxon test (ns: no significance, *:
0.01 < p ≤ 0.05, **: 0.001 < p ≤ 0.01, ***: 0.0001 < p ≤ 0.001,
****: p ≤ 0.0001). Sub-figure G shows t-SNE plot of estimated
immune abundance, color coded by cluster.
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3.2.3 There are 3 immune patterns of osteosarcoma
K-means clustering of immune cell proportions in osteosarcoma tumors indi-
cates the existence of three distinct immune classes (Figure 3.1D), namely: Cluster
1, which has the highest proportions of CD8 T cells, γδ T cells, M1 Macrophages,
Mast cells and Plasma cells and the lowest proportion of M0 Macrophages; Clus-
ter 2, in which the percentage of M0 Macrophages is the highest; and Cluster 3,
which has the highest percentage of M2 Macrophages. A t-SNE plot of immune
cell proportions suggests that K-means clustering algorithm successfully separates
osteosarcoma patients with different immune patterns (Figure 3.1G).
3.2.4 Cluster 2 has the worst survival outcome among all clusters
While there is no significant difference in gender, age and proportion of metas-
tasis at diagnosis between clusters (Figure 3.2A, B, F), we observe some differences
in survival outcomes among clusters.
Kaplan-Meier curves indicate that cluster 2 has the worst survival probability
throughout time out of all clusters (Figure 3.2G). In addition, cluster 2, along with
cluster 1, has higher percentage of dead patients at the last time of follow up than
cluster 3 (Figure 3.2C). Interestingly, cluster 2 also has the lowest immune scores
compared to other clusters (Figure 3.1F).
Cluster 3 appears to have the best outcome among clusters. It has the lowest
percentage of dead patients at the last time of follow up among all clusters (Figure
3.2C), and better survival rate than cluster 2 over time (Figure 3.2G) with p-value
0.07 from the log-rank test.
Cluster 1, which has the highest amount of CD8 T cells, γδ T cells, M1







Figure 3.2. Clinical characteristics of clusters and relationship be-
tween clinical features of osteosarcoma. Sub-figure A-E show
percentage of patients by gender (A), metastasis at diagnosis (B),
vital status at the last time of follow-up (C), Huvos grade (D), pri-
mary tumor location (E), in the 3 clusters. Sub-figure F shows a
boxplot of patients’ age at diagnosis in each cluster. Sub-figure G
displays Kaplan-Meier curves of overall survival across 3 clusters.
Sub-figures H-K shows the association between clinical features, H:
percentage of alive and dead patients by metastasis at diagnosis, I:
percentage of alive and dead patients by Huvos grade, J: percent-
age of low and high Huvos grade by tumor location, K: boxplot
of age at diagnosis by gender, with asterisks indicating significant
difference from Mann-Whitney-Wilcoxon test (ns: no significance,
*: 0.01 < p ≤ 0.05, **: 0.001 < p ≤ 0.01, ***: 0.0001 < p ≤ 0.001,
****: p ≤ 0.0001).
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ter 2 (p = 0.16, Figure 3.2G). However, cluster 1 seems to have worse outcome
than cluster 3 due to its higher percentage of dead patients at the last time of
follow up (Figure 3.2C). It is worth noting that there is no significant difference in
the survival rate between cluster 1 and 3 according to the log-rank test (p = 0.5,
Figure 3.2G).
3.2.5 There is a relationship between certain clinical features of os-
teosarcoma
The Chi-square test and Mann-Whitney-Wilcoxon test show a relationship be-
tween vital status and metastasis at diagnosis (p = 0.001, Figure 3.2H), vital status
and Huvos grade (p = 0.036, Figure 3.2I), which is a grading system to evaluate
a patient’s response to chemotherapy based on the percentage of necrosis in the
tumor after treatment, and between gender and age (p = 2.3e−4, Figure 3.2K)
where male patients are older on average. We observe that patients with metas-
tasis at diagnosis have much higher percentage of being dead at the last time of
follow up than patients without metastasis (Figure 3.2H). This makes perfect sense
since metastases have been known to associate with late stages of tumor and poor
prognosis in many cancers. The other clinical feature with a relation to vital sta-
tus is Huvos grade. Higher percentage of patients with high Huvos grade (3-4)
are alive at the last time of follow up than patients with low Huvos grade (1-2)
(Figure 3.2I), which is reasonable since a high Huvos grade means good response
to chemotherapy. Figure 3.2J suggests that primary osteosarcoma tumors in the
arm respond more poorly to chemotherapy than leg tumors, as illustrated by the
high proportion of Huvos grade 1-2 in arm tumors. However, it is important to
note that primary osteosarcoma tumors happen more often in the leg than in the
arm (Figure 3.2E), and the observation in Figure 3.2J is based on a small number
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of arm tumor samples (n = 8), thus the relationship between tumor location and
Huvos grade is not considered significant by the Chi-square test (p = 0.18).
3.2.6 Immune score does not relate to vital status directly, but does
relate to survival probability over time
Figure 3.3D indicates no clear difference in immune score between alive and dead
patients at the last time of follow up. However, Kaplan-Meier curves of high and
low immune score with a median cut-off reveal that the high immune score group
has a better outcome (Figure 3.3E). The log rank test supports this observation
with a p-value of 0.03. Thus, higher immune score is associated with better survival
probability throughout time. This is consistent with the observation of outcome
in the clusters. Cluster 2 has significantly lower immune score than cluster 1 and
3 (Figure 3.1F), with p-values of 5e−9 and 2.1e−5 from Mann-Whitney-Wilcoxon
test, and accordingly worse overall survival probability over time than cluster 1 and
3 (Figure 3.2G). Cluster 1, with the highest average immune score among clusters
(Figure 3.1F), even though has about the same proportion of dead patients at the
last time of follow up as cluster 2 (Figure 3.2C), shows better survival time than
cluster 2 (Figure 3.2G).
3.2.7 Relationship between immune infiltrates and survival outcome in
osteosarcoma
The Mann-Whitney-Wilcoxon test shows that there is a significant difference
in the level of γδ T cells and Mast cells between alive and dead patients at the
last time of follow up, with p-values of 0.045 and 0.022, where dead patients are
associated with higher percentages of γδ T cells and Mast cells than alive patients






Figure 3.3. Relationship of immune infiltrations with survival in os-
teosarcoma. Sub-figure A displays violin plots of fractions of γδ
T cells, Mast cells, Dendritic cells, NK cells, CD8 T cells between
alive and dead patients. Sub-figures B, C, E, F show Kaplan-Meier
curves of overall survival between 2 groups, B: high vs low Dendritic
cells, C: high vs low M0 Macrophages, E: high vs low ESTIMATE
immune score, F: high vs low CD8 T cells. Sub-figure D shows
a boxplot of ESTIMATE immune scores between alive and dead
patients. Note: asterisks indicate significant difference from Mann-
Whitney-Wilcoxon test (ns: no significance, *: 0.01 < p ≤ 0.05,
**: 0.001 < p ≤ 0.01, ***: 0.0001 < p ≤ 0.001, ****: p ≤ 0.0001).
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survival status in osteosarcoma. We observe higher level of NK cells (p = 0.063),
CD8 T cells (p = 0.1) and lower level of Dendritic cells (p = 0.052) in alive patients
than in dead patients (Figure 3.3A).
Kaplan-Meier curves (Figure 3.3B, C, F) and the log rank test indicate an as-
sociation between survival outcomes and levels of Dendritic cells, M0 Macrophages
and CD8 T cells, with a p-value of 0.01, 0.04 and 0.04, respectively. Low Dendritic
cells, low M0 Macrophages and high CD8 T cells are associated with better survival
probability over time in osteosarcoma patients. This is again consistent with the
outcome of the clusters where cluster 2, with the highest level of M0 Macrophages
and lowest CD8 T cells, has the worst overall survival.
Overall, we found that γδ T cells, Mast cells, Dendritic cells, M0 Macrophages,
NK cells and CD8 T cells have a relationship with the survival of osteosarcoma
patients.
3.2.8 Association of immune infiltrates with other clinical features
We see no significant relationship between age or metastasis at diagnosis and the
frequencies of immune cells. However, we notice an association of M1 Macrophages
and CD8 T cells’ frequencies to metastasis-free survival. High levels of M1 Macrophages
and CD8 T cells are associated with better metastasis-free survival probability
across time in osteosarcoma (Figure 3.4A, B), with p-values of 0.05 and 0.08
from the log-rank test, respectively. This means that patients with more M1
Macrophages and CD8 T cells are less likely to develop metastasis or die at any
given time than patients with low percentage of these cells.
A relationship between some immune infiltrates and other clinical features of
osteosarcoma has also been observed. Higher level of NK cells is associated with




Figure 3.4. Association of immune infiltrations and other clinical
features. Sub-figures A and B show Kaplan-Meier curves of
metastasis-free-survival in cohort 1 between 2 groups, A: high vs
low M1 Macrophages, B: high vs low CD8 T cells. Sub-figures C-
F are boxplots to indicate relationship of immune infiltrates with
Huvos grade (C), primary tumor location (D and E), and gen-
der (F). Note: asterisks indicate significant difference from Mann-
Whitney-Wilcoxon test (ns: no significance, *: 0.01 < p ≤ 0.05,
**: 0.001 < p ≤ 0.01, ***: 0.0001 < p ≤ 0.001, ****: p ≤ 0.0001).
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have higher percentage of Plasma cells and Dendritic cells than patients with leg
tumors (Figure 3.4D, E), with p-values of 0.046 and 0.033. Lastly, female patients
are shown to have higher frequency of Neutrophils (Figure 3.4F), with p-value
0.0016.
3.2.9 Expression level of genes encoding PD-1, INF-γ, CTLA4, TNF,
IL1-β, IGF1, IL-6 and RUNX2 are significantly different for some
clusters
We use the gene expression values for some important proteins, and we analyze
gene expression value of the proteins separately for cohort 1 and 2 because they
have different data types: RNA-Seq and microarray, respectively.
Programmed cell death protein 1 (PD-1) is a type of protein on T cells and
cancer cells use it to bind with PD-1 ligand (PD-L1) and PD-2 ligand (PD-L2) to
escape cell death by immune cells. There is a high correlation between PDCD1
gene, which encodes PD-1 protein, and CD8 T cells in both data sets with corre-
lation coefficient of 0.70 and 0.77, respectively, and p-values less than 0.05 (Figure
3.6). As a result of this correlation, PDCD1 is the highest in cluster 1 (Figure
3.5A1, B1). Cluster 1 also has the highest expression of CTLA4 gene (Figure
3.5A3, B3) that encodes Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4),
which is a member of immunoglobulin superfamily and has been found to signif-
icantly associate with the risk of osteosarcoma [131, 132]. Moreover, we see that
gene expression value of CTLA4 is significantly correlated with CD8 T cells in
osteosarcoma tumors (Figure 3.6).
Interferon γ (INF-γ), encoded by IFNG gene, has antiviral, immunoregulatory,
and anti-tumor properties in the immune system and is secreted by mostly T cells
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Figure 3.5. Gene expression values of important proteins in the clus-
ters. Sub-figures (A1–A7) and (B1–B7) show the gene expression
values that come from cohort 1 and cohort 2 data sets, respectively.
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Figure 3.6. Correlation and distribution of important proteins in the
clusters. Sub-figures A and B represent the cohort 1 and cohort
2 data sets respectively.
and NK cells [133]. Importantly, CD8 T cells frequency and PDCD1 gene expres-
sion are significantly correlated with IFNG gene expression so that cluster 1 has
the highest level of IFNG compared the other clusters (Figure 3.5A2, B2). Be-
side these, we do not see any significant correlation between expression levels of
CD274 and PDCD1LG2 genes, that encodes PD-L1 and PD-L2 respectively, with
the expression levels of PDCD1 and IFNG, and the percentage of CD8 T cells in
osteosarcoma tumors (Figure 3.6).
Tumor necrosis factor (TNF) is a cytokine that is mainly produced by Macrophages
and has crucial roles in tumor development and tumor progression inducing apop-
tosis, necrosis, angiogenesis, immune cell activation, differentiation, and cell migra-
tion [134]. We notice that cluster 2 has the lowest TNF gene expression among
clusters, while cluster 1 and 3 have roughly similar average expression of this gene
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(Figure 3.5 A4, B4). In addition, we analyze gene IL1B that encodes cytokin pro-
tein Interleukin-1 beta (IL-1β), which is produced by activated Macrophages [135],
and see that IL1B gene expression is the lowest in cluster 2 and the highest in
cluster 3 (Figure 3.5 A6, B6).
Beside these, Insulin-like growth factor 1 (IGF-1) is a hormone that has impor-
tant function in the development and function of many tissues and it has been used
as a diagnostic marker for osteosarcoma [136, 137]. Similar to TNF and IL1B genes
expression, cluster 2 has the lowest amount of IGF1 among other clusters (Figure
3.5 A5, B5). Furthermore, we examine RUNX2 oncogene that is associated with
amplifications and it has been found to correlate to poor response to chemotherapy
in osteosarcoma [138, 139]. In our analysis, cluster 1 has the lowest amount of
RUNX2 gene and cluster 2 and 3 show almost similar expression of RUNX2 gene
(Figure 3.5 A7, B7).
3.3 Discussion
The findings from analyses using estimated immune infiltrations in osteosar-
coma have varied among studies, perhaps due to the small number of osteosarcoma
tumors with available gene expression data in the literature. In this study, we find
that infiltration of CD8 T cells, NK cells and M1 Macrophages have a positive asso-
ciation with prognosis, while infiltration of γδ T cells, Mast cells, M0 Macrophages
and Dendritic cells have a negative association with prognosis. Yu et al [121] also
illustrates that high level of CD8 T cells is a good prognosis in their survival anal-
ysis, and results from [86] and [80] indirectly suggest the positive prognostic value
of CD8 T cells. Tang et al [86] reports that CD8 T cells infiltration has a positive
correlation with CXCR3 expression which is related to good prognosis. Khader et
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al [80] shows that low-risk patients have high level of CD8 T cells and NK cells,
which supports with our conclusion on these cells. In agreement with our findings
on prognostic value of M1 Macrophages, Song et al [79] demonstrates that high
level of M1 Macrophages is associated with good prognosis, while Zhang et al [85]
and Tang et al [86] imply the same from their results. Our conclusion about M0
Macrophages aligns with the results from [85] and [86], but contradicts with the
finding from [128] that abundance level of M0 Macrophages is positively correlated
with survival.
The observable difference in outcomes between clusters are likely due to the
relationship between immune infiltrates and prognosis in osteosarcoma, because we
cluster the patients based on their immune composition. Our results indicate that
cluster 2 has the worst outcome, while cluster 3 seems to have the best outcome
among clusters. The main difference in immune composition between these two
clusters is that cluster 2 has much higher percentage of M0 Macrophages, and
lower percentage of CD8 T cells and M1 Macrophages than cluster 3. In general,
we found that high levels of CD8 T cells and M1 Macrophages are associated
with good prognosis, while a high level of M0 Macrophages correlates with poor
prognosis in osteosarcoma. These results make sense because CD8 T cells are known
to kill cancer cells directly [9, 12] and M1 Macrophages exhibit anti-tumor effects
by producing cytokines that inhibit osteosarcoma growth [140]. These facts could
also explain the observed differences between the outcomes of patients in clusters
2 and 3.
Meanwhile, cluster 1 has worse outcome than cluster 3, but better outcome than
cluster 2. This could be due to the fact that cluster 1 has both high level of immune
cells associated with good prognosis such as CD8 T cells and M1 Macrophages, and
high level of immune cells associated with poor prognosis according to our results
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such as γδ T cells and Mast cells. High infiltration of mast cells have been associated
with poor prognosis, low survival and increased metastasis in many cancers [141],
while γδ T cells show dual effects on cancer growth [142]. Both mast cells and γδ
T cells promote tumor development by supporting angiogenesis through angiogenic
factors production [141, 142]. Mast cells also produce proteases, which lead to
extracellular matrix degradation and tissue remodeling, and thus promote tumor
growth [141]. γδ T cells have been reported to secrete TGF-β [142], which is a
pro-tumor cytokine in osteosarcoma [17, 20, 143]. Overall, the clinical outcomes of
the clusters are consistent with our findings and biological knowledge on prognostic
values of immune cells in osteosarcoma.
On the other hand, we did not observe any difference in age or metastasis at
diagnosis between clusters. This can be explained by the lack of correlation between
immune infiltrates and these clinical variables, which suggests that the immune
composition of the primary tumor has no effect on age or metastasis status at
diagnosis.
Our results indicate that cluster 2 has the worst outcome, while cluster 3 seems
to have the best outcome among clusters. It is interesting to note that the immune
patterns in cluster 2 and 3 are fairly similar (Figure 3.1D), with the main differ-
ence being cluster 2 has much higher percentage of M0 Macrophages and lower
percentage of M2 Macrophages than cluster 3. Since we found that a high level
of M0 Macrophages correlates with poor prognosis, this could be an explanation
for the difference in outcome between clusters 2 and 3. Cluster 1, which has very
different immune patterns from clusters 2 and 3, has worse outcome than cluster 3
but better outcome than cluster 2. This could be due to the fact that cluster 1 has
both high level of immune cells with good prognosis such as CD8 T cells and M1
Macrophages, and high level of immune cells with poor prognosis such as γδ T cells
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and Mast cells. Overall, the clinical characteristics of the clusters are consistent
with our findings about prognostic values of immune cells in osteosarcoma.
Immune checkpoints have an important role in the immune system to prevent
autoimmune diseases, but unfortunately they can allow immune tolerance against
tumors. PD-1 and CTLA-4 are the main checkpoints that tumor cells use to block
immune system [144, 145, 146]. Blocking PD-1 pathway has improved oncological
survival of several patients with metastatic cancers, including melanoma, renal cell
carcinoma, and colon cancer [147, 148]. Also, targeting CTLA-4 in patients with
metastatic melanomas demonstrates significant development about overall survival
[149].
It has been reported that osteosarcoma patients treated with an anti PD-1 drug,
Pembrolizumab, show some improvement in disease progression [150]. Combination
of PD-1 and CTLA-4 blockade therapy in bone sarcoma have shown better response
compared to single checkpoint inhibitor therapy [151]. Note, patients in cluster 1
have the highest expression levels of IFNG, PDCD1 and CTLA-4 that are signif-
icantly correlated with CD8 T cells (Figures 3.5 and 3.6), and it has been shown
that INF-γ increases the CD8 T cells expansion [152]. Thus, patients in cluster 1
might respond well to combination of PD-1 and CTLA-4 blockade therapies.
It has been suggested in several studies that bacteria are able to activate anti-
tumor immune responses [153, 154]. In a study with combination of Bacillus
Calmette-Guerin(BCG) injection and tumor vaccine, 18% of the patients remained
alive and disease-free and it has been reported that bacterial vaccine caused in-
creased level of immunoregulatory cytokines such as TNF-α, IFN-γ, and IL1-β
that might be involved in inducing tumor regression [155]. As a result, bacterial
vaccine and inactivated tumor cells injection can be thought of as a treatment that
activates anti-tumor immune responses [9]. In our results, cluster 2 has the lowest
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amount of gene expression level of immunoregulatory cytokines TNF-α, IFN-γ, and
IL1-β (Figure 3.5) so that tumors in this cluster might be treated with bacterial
vaccine. Otherwise, targeting RUNX2 oncogene with chemotherapy is suggested as
a new therapeutic approach to osteosarcoma patients in recent studies [156, 139]
and cluster 2 has the highest amount of RUNX2 gene expression values compared
to other clusters (Figure 3.5A7-B7) so with the help of further studies, tumors
similar to those in cluster 2 also might be good candidates to treat with targeting
RUNX2 in conjunction to standard chemotherapy.
Targeting tumor associated macrophages (TAM) is another alternative treat-
ment method for osteosarcoma tumors and treatments that suppress M2 Macrophages
phenotype or block the polarization of M1 Macrophages to M2 Macrophages have
shown positive results in several studies [10, 157, 158, 159]. Thus, tumors in cluster
3, which has the highest amount of M2 macrophages (Figure 3.1D) might respond
well to treatments that target TAMs.
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C H A P T E R 4
DATA-DRIVEN MATHEMATICAL MODEL OF
OSTEOSARCOMA
As mentioned in chapter 1, even though several mathematical models have been
developed to study the initiation and progression of many cancer types, there are
currently no mathematical models for the progression of osteosarcoma, to the best
of our knowledge. In chapter 3, we found that there were three distinct groups of
immune patterns of osteosarcoma primary tumors. In this chapter, we develop a
data-driven mathematical model of osteosarcoma based on the interactions between
various components of the tumor microenvironment such as cancer cells, necrotic
cells and immune cells, and use a system of ordinary differential equations (ODEs)
to represent these interactions [92].
We then investigate the differences in the tumor growth of patients belonging
in three distinct groups of immune patterns, which are obtained from chapter 3.
We calculate the group-specific parameters from data in each group and use the
previously estimated immune abundances as inputs in the mathematical model.
Lastly, we analyze the dynamics of tumors in each group to find relationships
that could potentially explain the effects of the tumor microenvironment on the
progression of osteosarcoma tumors.
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4.1 Materials and Methods
We built a kinetic model based on the key interactions between the immune
system and osteosarcoma cells. In particular, we utilized a system of ordinary
differential equations to study the changes in population of the various components
of tumor microenvironment throughout time in units of days. For biochemical
processes A + B → C, we apply the mass action law dC
dt
= λAB, where λ is the
production rate of C from A and B. For all the equations in our model, the symbol
λ denotes proliferation, activation, or production rates, and the symbol δ denotes
inhibition, decay, or death rates. The variables in the model are given in Table 4.1
and their interactions are illustrated in Figure 4.1.
4.1.1 Cytokines
We modeled the dynamics of cytokines through the rate at which they are
produced and their natural decay. We assumed that cytokine production rates are
proportional to the population of cells that produce them, similar to [160], and that
cytokine decay rates are proportional to their own population, which is a common
approach [55, 56, 57, 160, 161]. In order to simplify the system of equations,
we combine some cytokines with similar functions and use the quasi-steady state
assumption on other cytokines.
We combine TGF-β, IL-4, IL-10, and IL-13 as µ1. TGF-β and IL-10 are secreted
by helper T cells, M2 macrophages, and cancer cells [15, 16, 18, 140, 162, 163]. IL-4
and IL-13 are secreted by helper T cells and M2 macrophages [15, 140, 164]. Thus,
we model the dynamics of µ1 as:
d[µ1]
dt
= λµ1Th [Th] + λµ1M [M ] + λµ1C [C]− δµ1 [µ1] (4.1)



























Figure 4.1. Interaction network of the tumor microenvironment in os-
teosarcoma. Activations and proliferations are shown by blue
arrows, and inhibitions are indicated by red arrows.
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Table 4.1: Model Variables. Names and descriptions of




TC Cytotoxic cells includes CD8+ T-cells and NK cells
Tr Regulatory T-cells
DN Naive dendritic cells
D Activated dendritic cells antigen presenting cells
MN Naive macrophages includes naive macrophages and monocytes




µ1 Cytokines group µ1 includes effects of TGF-β, IL-4, IL-10 and IL-13
µ2 Cytokines group µ2 includes effects of IL-6 and IL-17
Iγ IFN-γ
helper T cells, and cancer cells [16, 19, 140, 163, 165], and IL-17 is produced by
helper T cells [15]. The corresponding equation for µ2 is:
d[µ2]
dt
= λµ2Th [Th] + λµ2M [M ] + λµ2C [C]− δµ2 [µ2] (4.2)
IFN-γ is secreted by helper T cells, cytotoxic T cells, and natural killer cells [12,
15, 166]. As a result, the equation for IFN-γ is written as:
d[Iγ]
dt
= λIγTh [Th] + λIγTc [Tc]− δIγ [Iγ] (4.3)
HMGB1 is passively released by necrotic cells [8, 30, 167, 168] and actively
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= λHM [M ] + λHD[D] + λHN [N ]− δH [H] (4.4)
We use the quasi-equilibrium state assumption on the other cytokines and es-
timate them to be proportional to the number of cells that produce them. IL-12
and IL-23 are both secreted by M1 macrophages and dendritic cells [12, 15, 140,
162, 163, 170]; therefore, we model the concentration of these cytokines as:
[IL-12] ≈ c1 × [M ] + c2 × [D] (4.5)
[IL-23] ≈ c3 × [M ] + c4 × [D] (4.6)
where c1, c2, c3, and c4 are constants.
4.1.2 Cells in the Tumor Microenvironment
Since mature immune cells are differentiated from naive immune cells, we model
the population of each mature immune cell to be proportional to its respective
naive immune cell, where the proportion is determined by the cells/cytokines that
activate the naive cells. Similar to the cytokine equations, for each mature immune
cell, we also include a natural death rate δcell.
Macrophages
Since macrophages have many phenotypes and are constantly changing their
phenotype, we model all macrophages together as one variable to avoid overly great
complexity. M1 and M2 macrophages are differentiated from naive macrophages
or monocytes. M1 macrophages are activated by IFN-γ [18, 162, 163], while M2
macrophages are activated by IL-4, IL-10, and IL-13 [16, 162, 163, 171], where
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λMIγ [Iγ] + λMµ1 [µ1]
)
[MN ]− δM [M ] (4.7)
By taking into account the activations from Equation (4.7) and introducing the
independent naive macrophage/monocyte production parameter AMN , we have the





λMIγ [Iγ] + λMµ1 [µ1]
)
[MN ]− δMN [MN ] (4.8)
T Cells and NK Cells
We model the following subtypes of T cells: helper T cells, regulatory T cells,
and cytotoxic cells, where cytotoxic cells include cytotoxic T cells and natural killer
cells.
Helper T cells are activated by dendritic cells, IL-12, and IL-23 [9, 12, 15,
172], and are inhibited by regulatory T cells, IL-10, and TGF-β [12, 14, 173, 174],
resulting in the equation:
d[Th]
dt
= (λThM [M ] + λThD[D]) [TN ]− (δThTr [Tr] + δThµ1 [µ1] + δTh) [Th] (4.9)
Regulatory T cells are activated by IL-10 and TGF-β [12, 175], hence their
dynamics are modeled by:
d[Tr]
dt
= λTrµ1 [µ1][TN ]− δTr [Tr] (4.10)
Cytotoxic cells (cytotoxic T cells and NK cells) are activated by helper T cells,
dendritic cells and IL-12 [8, 9, 10, 12, 16, 176, 177] and are inhibited by regulatory
T cells, IL-10, and TGF-β [9, 13, 163, 175]. The corresponding equation is:
d[Tc]
dt
= (λTcTh [Th] + λTcM [M ] + λTcD[D]) [TN ]− (δTcTr [Tr] + δTcµ1 [µ1] + δTc) [Tc]
(4.11)
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Combining all the activations from Equations (4.9)–(4.11) as well as adding
parameter ATN for the independent production rate of naive T cells, we obtain the
equation for naive T cells:
d[TN ]
dt
=ATN − (λThM [M ] + λThD[D]) [TN ]− λTrµ1 [µ1][TN ]
− (λTcTh [Th] + λTcM [M ] + λTcD[D]) [TN ]− δTN [TN ]
(4.12)
Dendritic Cells
Dendritic cells are activated by cancer cells and HMGB1 [9, 29, 30, 31, 32].
However, cancer cells can also promote apoptosis in dendritic cells through many
tumor-derived factors, such as gangliosides, neuropeptides, etc. [170]. By introduc-
ing the independent production rate of naive dendritic cells ADN , we can describe
the dynamics of naive and mature dendritic cells with the following system:
d[D]
dt
= (λDC [C] + λDH [H]) [DN ]− (δDC [C] + δD) [D] (4.13)
d[DN ]
dt
= ADN − (λDC [C] + λDH [H]) [DN ]− δDN [DN ] (4.14)
Cancer Cells
Osteosarcoma cells are typically of osteoblastic origin and are characterized by
abnormally high proliferation and low apoptosis. We denote the high proliferation
rate of cancer cells as λC .
Osteosarcoma growth is promoted by IL-6, IL-17, and TGF-β [12, 17, 18, 19,
20, 143, 165, 178]. Tumor cells are killed by cytotoxic cells [9, 179, 180], while their
growth is inhibited by IFN-γ [9, 10, 166]. In the mathematical modeling of cancer,























Necrotic cells, which are cells that go through the process of necrotic cell death,
are promoted by cancer cells since, when cancer cells are killed by cytotoxic cells,
a proportion of them become necrotic cells. In particular, the “production” rate






δCTc [Tc] + δCIγ [Iγ] + δC
)
[C]− δN [N ] (4.16)
4.1.3 Data of the Model
In the last chapter, we applied CIBERSORTx B-mode on the gene expression
data sets from two cohorts, TARGET and GSE21257, to estimate the immune cell
abundances within osteosarcoma tumors. Then, K-means clustering was applied
on the estimated immune cell fractions. As a result, we found that there were
three distinct immune patterns of osteosarcoma tumors. In this chapter, we use
the same cluster assignment for the TARGET data with 88 samples and use our
mathematical model to study the dynamics of the tumor microenvironment of each
cluster from the initial time of diagnosis until reaching their steady state. The
general workflow of this study is described in Figure 4.2, and the average immune
fractions of various cell types in each cluster are shown in Figure 4.3, where the





































Figure 4.2. The general workflow of this study. Given the gene expres-
sion data of tumors, immune cell fractions were estimated using
CIBERSORTx B-mode. Then, K-means clustering was applied to
find three clusters with distinct immune compositions. For each
cluster, the populations of immune, cancer, and necrotic cells were
derived from immune fractions and clinical information. These cell
populations and cytokine expression levels were used as input (ei-
ther as the initial conditions or steady states) in the system of
ODEs to find the dynamics of the components of the tumor mi-
croenvironment in each cluster.
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Figure 4.3. The immune cell fractions used in the model. Clusters were
derived based on differences in 22 immune cell types of osteosar-
coma tumors.
The outputs of CIBERSORTx only provide the fractions of each immune cell
within the tumor tissue; however, we need the number of immune cells along with
the number of cancer and necrotic cells as inputs to our model. Thus, we download
the supplementary data of the TARGET project, which has information on the
percentage of normal, stroma, tumor, and necrotic cells of each sample. We use
the percentage of normal cells to represent the percentage of total immune cells in
the sample.
First, we convert the immune cell fractions to the immune cell population by
multiplying the fractions with a scaling factor αdim. Then, knowing the percentage
of total immune cells, cancer cells, and necrotic cells, we derive the population of
cancer and necrotic cells from the population of total immune cells. For example,
given the total immune population I, the cancer and necrotic cell abundance can
be calculated as
C = I × % of cancer cells
% of total immune cells
(4.17)
N = I × % of necrotic cells
% of total immune cells
(4.18)
where C and N are the cancer and necrotic cell population, respectively.
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To choose a reasonable value for αdim, we first estimate the average osteosarcoma
tumor volume. We find the mean volume of Ewing sarcomas to be 275 mL based on
the tumor volumes given in [183], and Ewing sarcoma has been reported to have a
similar volume to osteosarcoma [184]. Thus, we estimate the average osteosarcoma’s
volume to be 275 mL.
Osteoblasts, which are the cells of origin of osteosarcoma, have a diameter of
20–50 m [185]; therefore, we approximate osteosarcoma cells to have an average
diameter of 35 m, resulting in an average of 6.4 × 109 osteosarcoma cells in os-
teosarcoma tumors. We then choose αdim = 1.765 × 108 to match the average
number of cancer cells among all patients in our data to 6.4× 109 cells. However,
it is important to note that αdim is simply a scaling factor and does not have any
effects on the dynamics of cells or on the relative cell abundance between clusters.
4.1.4 Parameter Estimation
Some parameters of our model, such as the decay/death rates of immune cells
and cytokines, are taken from available research (more details in Appendix A.2.1),
while others are estimated. We follow the common approach from mathematical
biological models to use assumptions on the steady state values of the system to
derive those unknown parameters [186, 187]. In particular, we make the assumption
that after a tumor reaches a very large size, the immune variation within the tumor
microenvironment is minuscule, and we denote this state as the steady state of our
system.
Different immune patterns of tumors, such as high or low levels of helper and
cytotoxic T cells in one group versus another group, indicate that the activation
rates of different T cell sub-types from naive T cells vary from one group of tumors
to another group. Hence, many parameters of the model, such as the activation
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rates of T cell sub-types, depend on the tumor immune profile, and therefore we
estimate the parameters separately for each cluster.
We assume the samples with a large number of cancer cells are at the steady
state. For each cluster, we use the 85th percentile of cancer abundance as the
cutoff, and calculate the steady state values for the cluster by averaging the values
from samples that have more cancer cells than this cutoff. Table 4.2 shows the
steady state values of every cluster.







1 6.236× 106 1.977× 107 4.926× 106 7.092× 106 3.675× 106
2 3.248× 107 1.842× 107 1.047× 107 1.973× 106 8.673× 105





1 2.292× 107 4.826× 105 9.865× 105 1.343× 1010 3.764× 108
2 3.155× 105 8.927× 105 7.135× 105 1.604× 1010 4.257× 108







1 0.868 21.510 2.067 5.076
2 0.049 20.714 1.611 4.948
3 0.263 23.663 1.371 4.453
Our assumption above asserts that the rate of change of our model’s variables
is 0 at the steady state, or equivalently dX
dt
= 0 at the steady state. With the
additional assumptions in Appendix A.2.1, as well as knowing the steady state
values of our model’s variables, we can derive parameter values for each cluster
using the fsolve function from the SciPy package in Python. The parameter values
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for each cluster are given in Table A.1.
4.1.5 Non-Dimensionalization
To remove the scale dependence and obtain additional numerical stability, we
apply non-dimensionalization on all equations of our system. For a model variable
X converging to the steady state value X∞, we create a non-dimensional variable
X such that X = X
X∞
. Then, X satisfies the equation dX
dt
= F (X, θ, t), where θ is
the vector of non-dimensional parameters. The full system of non-dimensionalized
equations are given in Appendix A.3.
To solve the non-dimensional dynamical system for each cluster, we apply the
odeint function from the SciPy package [188], with the initial conditions from a
data point of interest from the TARGET data set.
4.1.6 Sensitivity Analysis
To evaluate the quality of our parameters through how they affect the dynam-
ics of the system, we perform a global gradient-based sensitivity analysis on all
parameters of our system.
For the non-dimensional system dX
dt
= F (X, θ, t) withN parameters θ = θ1, . . . , θN ,
the (first order) sensitivity si of parameter θi was defined as the gradient of the





We calculate the sensitivity si for each parameter at the steady state of the
equation for two quantities of interest: cancer cell abundance and total cell abun-
dance. Consider the general steady state system as F (X∗, θ) = 0, with X∗ being
the equilibrium values of our model’s variables. The sensitivity vector s can be
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obtained analytically by differentiating the steady-state equation with respect to








where ∇F (X∗, θ) is the Jacobian matrix of F (X∗, θ) with respect to X. Then, to
compute sensitivity vector s at equilibrium, or equivalently ∂X
∗
∂θ
, we simply need to
numerically invert ∇F (X∗, θ).
Generally, si varies for different values of the parameter set; thus, we define the






where the integral is evaluated numerically using sparse grid points [190, 191].
Since we made many assumptions to derive the parameter values for our model
and different assumptions can lead to different parameter values, we vary these
assumptions by a scaling factor of 0.01 to 100 for K times and obtain the local
sensitivity Ski , with k = 1, . . . , K, for parameter θi derived from the k
th set of new
assumptions. Then, the global sensitivity Si of parameter θi is a weighted average







where wk is chosen so that the parameter values that are closer to the original
parameter set have larger weights and the parameter values that are very different
from the original parameter set have smaller weights. This method of choosing wk
is based on the idea of the weighted average of local sensitivities in [189].
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4.2 Results
We obtain the dynamics of the components in the tumor microenvironment
by solving the above mentioned system of ODEs with parameters derived from the
cancer patient data using the steady state assumption as mentioned in Section 4.1.4.
Given non-negative initial conditions and non-negative parameters, the solution of
the systems remains non-negative and globally bounded (Appendices A.1.2 and
A.1.3).
4.2.1 Dynamics of the Tumor Microenvironment
We are interested in exploring the dynamics of different components of the
osteosarcoma microenvironment as well as the difference in cancer progression be-
tween clusters. Hence, we want to model the dynamics with similar initial cancer
populations among clusters. We first choose the sample with the smallest cancer
population in cluster 1, and then choose a sample from cluster 2 and 3 that has
the most similar cancer population to the chosen sample in cluster 1. We use these
samples as the initial conditions for their corresponding cluster. Table 4.3 shows
the dimensionless initial condition values of each cluster.
We observe that, as the cancer population grows, helper T cells, dendritic cells,
cytotoxic cells, and IFN-γ populations first increase and then decrease over time.
This makes sense biologically since, in the early stage of cancer, naive dendritic
cells come in contact with tumor antigens, inducing the activation and increase in
the number of dendritic cells [7, 9]. Dendritic cells present tumor antigens to helper
T cells and cytotoxic cells and activate them [192], resulting in an increase of these
cells. Helper T cells and cytotoxic cells then produce IFN-γ [12, 15, 166], leading
to this cytokine’s increased abundance.
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1 2.367 1.005 0.019 0.794 0.764 0.828 1.122
2 0.954 0.753 1.299 1.451 2.313 0.062 0.071
3 0.866 1.104 0.572 0.340 0.484 0 1.643








1 0 0.020 0.160 2.394 1.104 1.806 1.059
2 0.693 0.005 0.018 0.859 1.307 3.259 0.988
3 0 0.014 0.0008 0.276 1.030 1.296 1.284
The switch in dynamics from increasing to decreasing in dendritic cells, helper T
cells, cytotoxic cells, and IFN-γ occurs around the same time that cancer cells start
growing fast. Contrastingly, the number of regulatory T cells decreases when these
cells increase and increases when these cells decrease. Hence, regulatory T cells start
increasing in density when the tumor is at its peak of growing. Regulatory T cells
have the role of modulating the immune system and consequently promote tumor
growth; therefore, we can expect the opposite dynamics to anti-tumor immune cells
and cytokines, such as dendritic cells, helper T cells, cytotoxic cells, and IFN-γ. In
general, it is important to study this switch in the dynamics since it can be used
as the predictor of the highest growth of cancer cells during tumor development.
On the other hand, the macrophage population first decreases and then in-
creases during osteosarcoma progression, while necrotic cells, HMGB1, along with
the cytokine groups µ1 and µ2 increase in population as cancer cells grow. As
both µ1 and µ2 support tumor growth, their population growth over time could
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contribute to the fast progression of osteosarcoma. Necrotic cells are mainly cancer
cells that were killed by cytotoxic cells or IFN-γ; thus, it is reasonable to see their
population grow over time. As a result, HMGB1, which is largely produced by
necrotic cells, increases in abundance as the tumor progresses.
Cluster 2’s cancer cells begin by growing more slowly than cluster 1; however, at
around 500 days, they start growing very fast and end up having the highest cancer
population at the steady state out of all clusters. The results of chapter 3 based
on the clinical information of the TARGET dataset also indicate that patients in
cluster 2 have the worst survival outcomes among the three clusters.
Figure 4.4 shows that cluster 2 has the lowest number of cytotoxic cells, macrophages,
and IFN-γ and the highest number of naive macrophages during tumor progres-
sion. A high population of cytotoxic cells and IFN-γ are generally associated with
a good prognosis because they directly kill cancer cells, while a high level of naive
macrophages have been found in chapter 3 to associate with poor prognosis. Clus-
ter 2 also has the slowest growth rate of necrotic cells. A high number of necrotic
cells means many cancer cells have been killed by the immune system and is an
indication of a good prognosis. Thus, cluster 2, with a slow growth rate of necrotic
cells, high growth rate of cancer, and the highest cancer population at the steady
state, has a poor prognosis based on our model’s dynamics.
Cluster 3 has the slowest cancer growth rate among all clusters and a smaller
cancer population at the steady state compared with cluster 2. Cluster 3’s necrotic
cells have the fastest growth rate and the highest population at the steady state out
of the 3 clusters. Hence, the dynamics of cluster 3 appear to be the most favorable.
This is in agreement with the findings on the survival outcomes of cluster 3 in the
previous chapter.































































































































































































































Figure 4.4. Dynamics of cells and cytokines in osteosarcoma tumors.
Evolution of the cells and cytokine population in the model is plot-
ted over the time in units of days. This figure shows the dynamics
of the variables of the model starting from the time of the first di-
agnosis of small tumors in each cluster until reaching their steady
state values, i.e., the average values of the largest tumors in the
same cluster. The different color lines describe the dynamics of
different clusters.
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group µ2, which has tumor-promoting effects, both initially and at the steady state
(Figure 4.4). Interestingly, cluster 3 also has the lowest population of helper T
cells and dendritic cells over time. These two cells are known to correlate with
good prognoses. If we were to simply look at the immune composition of the
patients in cluster 3, we might make the wrong prediction on their prognosis due to
the low abundance of certain immune cells with good prognostic values. Therefore,
it is important to take into consideration the interaction between immune cells and
cancer cells, and investigate the dynamics of cancer in addition to studying the
immune composition.
Cluster 1 has a high cancer growth rate from the beginning and thus its cancer
population reaches the steady state faster than the other clusters. However, its
cancer cells do not reach as high population at the steady state as the cancer cells
in cluster 2. Cluster 1 has the highest levels of both immune cells and cytokines
with good prognoses, including cytotoxic cells, helper T cells, dendritic cells, and
IFN-γ, and those with poor prognoses, such as regulatory T cells and µ2 during
tumor progression. Thus, it is again necessary to look at the interactions within
the tumor microenvironment for such clusters.
We observe that µ1 and µ2 grow fast and reach the steady states very quickly
in cluster 1. Since both µ1 and µ2 promote tumor proliferation, this could be the
reason why cancer cells quickly reach the steady state in cluster 1. Overall, since
cluster 1 has a lower cancer population at the steady state compared with cluster 2
but a higher cancer growth rate than cluster 3, its cancer dynamics are worse than
cluster 3 but better than cluster 2, which aligns with the results of chapter 3.
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Most sensitive immune parametersMost sensitive parametersA B
Figure 4.5. Sensitivity analysis. (A) The sensitivity level of the most sensi-
tive parameters for cancer and total cell population at the steady
state. (B) The most sensitive parameters associated with immune
cells. The most sensitive parameters for each cluster are shown in
each row of plots.
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4.2.2 Sensitivity Analysis
We perform global sensitivity analysis with parameters derived from patient
data with the steady state assumption in each cluster. The sensitivity analysis is
performed on the dimensionless system, and evaluated at the steady states. We are
interested in finding which parameters in our system strongly affect the growth of
tumors, and thus we use the cancer population and total cell population as variables
of interest in the sensitivity analysis.
Figure 5.3A presents the six most sensitive parameters in every cluster. Since
we also want to study the effects of the immune system on cancer progression, we
look at the five most sensitive parameters from the immune cells equations as well.
Therefore, we plot the top five most sensitive parameters excluding the parameters
from the cancer cell Equation (4.15) and necrotic cell Equation (4.16) (Figure 5.3B).
The most sensitive parameters across the three clusters are the cancer prolif-
eration and inhibition parameters in the cancer Equation (4.15). As expected, an
increase in any of the cancer proliferation parameters (λC , λCµ1 , λCµ2) results in an
increase in the number of cancer cells, and an increase in any cancer inhibition
parameters (δCTc , δCIγ , δC) results in a decrease in the number of cancer cells. It
is worth noting that all sensitive parameters presented in Figure 5.3 have similar
effects on cancer populations as on total cell populations.
The most sensitive immune parameters are activation and the decay rates of
macrophages and regulatory T cells for all clusters. An increase in any activation
rates of macrophages and regulatory T cells leads to higher cancer and total cell
numbers, while an increase in their decay rates causes a decrease in these quantities
of interest. This implies that both macrophages and regulatory T cells have tumor-
promoting effects.
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Since regulatory T cells inhibit helper T cells and cytotoxic cells, they hinder
IFN-γ production and, thus, down-regulate cytotoxic cells and IFN-γ’s ability to
kill cancer cells. Macrophages, on the other hand, have both anti-tumor phenotype
(M1 macrophages) and pro-tumor phenotype (M2 macrophages). However, the
predominant portion of macrophages in the patient data across all three clusters is
M2 macrophages (Figure 4.3), which can cause the main effect of macrophages in
our model to be pro-tumor.
4.2.3 Dynamics with Varying Assumptions
Since we made some assumptions in order to derive the parameter values for
each cluster, we want to see how the dynamics of cancer population would change
when we vary these assumptions. Based on the results of the global sensitiv-
ity analysis, we determine that the parameters in the equations of cancer cells,
macrophages, and regulatory T cells are the most sensitive parameters. We vary
each assumption relating to these sensitive parameters (Equations (A.15)–(A.19))
by five times in both directions (scale five-times bigger or five-times smaller) and
observe how the progression of cancer changes with the new assumptions (Figure
4.6). For example, since λC and λCµ1 are sensitive parameters, we vary the assump-
tion λC = 40λCµ1µ
mean




1 , λC = 8λCµ1µ
mean
1 , (4.23)
where the cancer dynamics with the original assumption (Equation (A.16)) is the
left plot in Figure 4.6A (scale = 1), and the cancer dynamics with the new assump-
tions (Equation (4.23)) are the middle and right plots in Figure 4.6A (scale = 1/5
and scale = 5).
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Figure 4.6. The dynamics of cancer when the assumptions of the sen-
sitive parameters are varied. (A-E) The cancer growth of all
three clusters for each assumption of sensitive parameters. The left
plot in every sub-figure is the original cancer dynamics, the middle
and right plots are the cancer dynamics obtained when the given
assumption is scaled by 1/5 and by 5, respectively.
80
We notice that when we vary the assumptions of the most sensitive parameters,
the time for the cancer population to reach the steady state changes by a relatively
small amount; however, the overall observation of the cancer dynamics between
clusters does not change (Figure 4.6). That is, these different assumptions lead
to the same observations: cluster 1’s cancer population reaches a steady state the
fastest among all clusters, cluster 2’s tumors grow slower than cluster 1’s at first
but then begin growing fast and result in the highest steady state population, and
cluster 3 has the most favorable cancer progression with the slowest growth of
cancer cells and one of the lowest steady state cancer populations.
The largest changes in the dynamics of cancer are due to the assumptions for











This assumption is based on the fact that M1 and M2 macrophages are activated
by IFN-γ and µ1, respectively, and thus the ratio of macrophages activated by IFN-
γ to macrophages activated by µ1 should be approximately equal to the ratio of
M1 to M2 macrophages. This is a reasonable assumption that uses patient data to
derive the activation rates of macrophages. We expect to see the ground truth ratio
of macrophages activated by IFN-γ to macrophages activated by µ1 to be close to
our assumption, rather than to differ by five times. Therefore, it is very unlikely
to observe cancer dynamics, such as in the middle and right plots in Figure 4.6E
with our data. On the other hand, the assumptions for the death rate of cancer
by IFN-γ and the apoptosis rate of cancer, δCIγI
mean
γ = 10δC , appear to have a
negligible to no impact on cancer progression (Figure 4.6D).
The shaded regions in Figure 4.6 denote the changes in dynamics when we varied
the most sensitive parameters (λC , λCµ1 , λCµ2 , δCTc , δCIγ , δC , λMIγ , λMµ1 , δM , λTrµ1 ,
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and δTr) by 10% in negative and positive directions. We observe that varying
the most sensitive parameters by 10% does not create large changes to the cancer
dynamics. Overall, Figure 4.6 shows that, when we change the assumptions of
the most sensitive parameters or vary the sensitive parameters themselves, the
observations we made about cancer development between clusters in Section 4.2.1
are not affected. Furthermore, even though several assumptions were made to
estimate the parameters, the dynamics of cancer do not greatly depend on these
assumptions.
4.2.4 Dynamics with Different Initial Conditions
For each cluster, we also look at the dynamics with different initial conditions
from the different samples within that cluster (Figure 4.7). We observe that differ-
ent initial conditions in a cluster lead to similar growth patterns of cancer. This
makes sense since the dynamics are determined by the parameters of the ODE sys-
tem, which are derived from the patient data through the steady state assumption
in each cluster. As a result, the cancer growth rates and patterns are similar among
patients within the same cluster but different among patients in different clusters.
Thus, if we know which cluster a patient belongs to, we can predict their cancer
growth more accurately than by using the same cancer progression model for all
patients.
To verify that the parameters in each cluster are what drives the dynamics of
the cluster, we examine the dynamics of each cluster with the initial conditions
from other clusters (Figure 4.8). In particular, we plot dynamics of cluster 1 with
the initial conditions in Table 4.3 from clusters 2 and 3. These cross-cluster initial
conditions quickly converge to the same dynamics, confirming that the dynamics








Figure 4.7. The dynamics with varying initial conditions. (A-C) The
dynamics of cells and cytokines with initial conditions from differ-











Figure 4.8. Dynamics with cross-cluster initial conditions. (A) The dy-
namics of cells and cytokines with parameters from cluster 1 and
initial conditions from clusters 2 and 3. (B) The dynamics of cells
and cytokines with parameters from cluster 2 and initial conditions
from clusters 1 and 3. (C) The dynamics of cells and cytokines with





Our results show that, as cancer cells grow in number, the helper T cell, den-
dritic cell, cytotoxic cell, and IFN-γ populations increase at first and then decrease
with time, while regulatory T cells first decrease in population and then increase.
This switch in the dynamics of immune cells happens around the time that cancer
cells have the fastest growth. Notably, we also find that, in order to make reason-
able predictions regarding the prognosis of cancer patients, it is necessary to study
the interactions between immune cells rather than to simply look at the abundance
of a certain immune cell type. This observation can be supported by [194], which
states that the immune response following from activation of T cells is dependent
on the presence of other immune protagonists, such as macrophages, implying that
the interactions between immune cells can affect the immune response.
Our results indicate that cluster 3 has the slowest cancer growth and a relatively
low population of cancer cells at the steady state. Meanwhile, cluster 2 has one
of the fastest cancer growth rates and, more importantly, the highest number of
cancer cells at the steady state. Thus, cluster 3 has the most favorable cancer
progression, and cluster 2 has the least favorable cancer progression. These results
are in agreement with the findings from clinical data in chapter 3 that cluster 3 has
the best outcomes and cluster 2 has the worst outcomes.
Our global sensitivity analysis shows that the rate at which cytotoxic cells kill
cancer cells has a large impact on the growth of osteosarcoma. Therefore, it is prob-
able that treatments that attempt to increase this rate of cytotoxic cells attacking
tumor cells, such as PD-1 or CTLA-4 inhibitors, would work well for osteosarcoma.
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In fact, a phase 2 trial reported that some improvement in cancer progression
was observed in osteosarcoma patients treated with the anti PD-1 drug, Pem-
brolizumab [195]. The combined treatment of PD-1 and CTLA-4 blockade therapy
has shown even better responses compared with single checkpoint inhibitors in bone
sarcoma [196].
In the mathematical modeling of cancers, one of the main challenges is the large
number of unknown parameters and a limited availability of data sets to derive
parameters from. To combat this challenge, many mathematical models adopt one
or a couple of the following approaches: assuming biologically feasible values for
some parameters, using estimated parameters from other diseases or rodent studies,
calibrating parameters to fit the biological behaviors from an experimental data set,
and varying the parameter values within a reasonable range to study the impact
of those parameters on the results. In our work, we acquire parameter values from
experimental studies in the literature and estimate the others using the steady
state assumption with the steady state values derived from patient gene expression
data. Importantly, we also perform global sensitivity analysis on the estimated
parameters.
All mathematical models thus far use the same parameters for all patients,
while our model estimates parameters separately for each cluster of patients with
distinctive immune compositions. Since patients with different immune composi-
tions have shown different prognoses and different responses to treatment [197, 198,
199, 200, 201], estimating the parameters for each cluster separately helps us model
the effects of immune cells on cancer growth and their responses to treatment more
accurately.
To avoid adding complexity to an already complex network, our study does
not model the healthy cells in the tumor microenvironment. While several math-
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ematical models for tumor growth study the competition between healthy cells
and cancerous cells [160, 202, 203, 204], these models typically only investigate a
small subset of immune cells, unlike our model, which focuses on many important
components of the immune system. Moreover, as the cancer self-proliferation rate
(λC) in our model is taken from osteosarcoma growth data in humans, which is
naturally the growth of tumors with the presence of healthy cells, this parameter
already encodes the inhibition of cancer growth due to competition with healthy
cells. Therefore, even though we do not explicitly model healthy cells, the impact
of healthy cells on cancer growth is incorporated implicitly through λC .
While it would be ideal to use time course data to derive the parameters in
each cluster, the availability of such data is currently limited, and so instead we
use the large tumors in each cluster as the steady state values to estimate these
parameters. Despite this limitation due to the lack of time course data, our model
still provides valuable insights on the progression of osteosarcoma and the impact
of the immune system on its growth, and many studies can build upon this one.
Ways to improve this model include utilizing partial differential equations to study
the growth of osteosarcoma tumors, both in space and in time, or applying different
parameter fitting algorithms [205, 206, 207, 208] to better match the dynamics of
the system to real patient data.
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C H A P T E R 5
INVESTIGATING OPTIMAL CHEMOTHERAPY
OPTIONS FOR OSTEOSARCOMA PATIENTS
THROUGH A MATHEMATICAL MODEL
In the last chapter, we have developed a data driven mathematical model for
the interaction network between key immune cells and cancer cells to investigate
tumors’ growth behaviors of three distinct groups of osteosarcoma tumors, grouped
based on their immune compositions, and group-specific parameters have been cal-
culated to discover differences in tumor growth between groups. In this chapter,
we extend our previous model by adding the interactions between the most com-
mon chemotherapy drugs for osteosarcoma and important cell types in the tumor
microenvironment in order to examine the effects of these drugs on osteosarcoma
tumors in each group.
Most chemotherapy treatments for osteosarcoma include one or a combination
of the following drugs: high dose Methotrexate (MTX), Doxorubicin (DOX) and
Cisplatin (CDDP). The most popular treatment regimen for adolescents is the
MAP regimen, consisting of all those three drugs [209, 210], and a widely used
treatment for older adults is a two-drug regimen of Doxorubicin and Cisplatin
[210]. This study investigates the response to these regimens through a data driven
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mathematical model, suggests optimal chemotherapy dosages, as well as compares
the behaviors of immune and cancer cells under various conditions such as resistance
to chemotherapy and different treatment start times.
5.1 Materials and Methods
5.1.1 Mathematical Model
We build upon the model in the previous chapter by adding the interactions of
the variables in that model with the following chemotherapy drugs: Methotrexate,
Doxorubicin and Cisplatin. The interaction network of these drugs with cells and
cytokines of osteosarcoma tumor microenvironment is shown in Figure 5.1. We
use exponential kill model, as introduced in [211], to describe how chemotherapy
affects the cancer microenvironment and model the change in population of the
new model’s variables throughout time in unit of day. The details of the effects of
chemotherapy drugs on immune cells and cancer cells are explained below (changes
to equations (A.1)-(A.14) are in bold).
Cancer cells
All chemotherapy drugs in our model aim to kill tumor cells, though they have
different mechanisms of action. Methotrexate hinders DNA synthesis in fast divid-
ing cancer cells by inhibiting folate dependent pathways [212]. Doxorubicin can kill
cancer cells by binding to DNA-associated enzymes, intercalating the base pair of
DNA’s double helix, and targeting many molecular targets such as topoisomerase
enzymes I and II, which results in DNA damage [213]. Cisplatin binds platinum to
































Figure 5.1. Interaction network with chemotherapy drugs. Activations,
proliferations or stimulations are indicated by blue arrows, and
inhibitions are indicated by red arrows. Chemotherapy drugs also
inhibit all immune cells (red arrows from drugs to immune cells
not shown).
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Table 5.1: Model Variables. Names and descriptions of




TC Cytotoxic cells includes CD8+ T-cells and NK cells
Tr Regulatory T-cells
Dn Naive dendritic cells
D Activated dendritic cells antigen presenting cells
MN Naive macrophages includes naive macrophages and monocytes




µ1 Cytokines group µ1 includes effects of TGF-β, IL-4, IL-10 and IL-13
µ2 Cytokines group µ2 includes effects of IL-6 and IL-17
Iγ IFN-γ
A1 Methotrexate Methotrexate concentration at tumor site
A2 Doxorubicin Doxorubicin concentration at tumor site
A3 Cisplatin Cisplatin concentration at tumor site
damage which leads to cell death in rapidly proliferating cells [214, 215].
Similar to [211, 216], we use saturation kill term (1− eβA) to model the direct
cytotoxic effects of chemotherapy drugs on cancer cells, where β is the drug efficacy
parameter, and A is the drug concentration at the tumor site. This is based on the
observation that at low concentration, the cancer killing effect of these drugs are
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almost linear, but at very high concentration the cancer killing effect plateaus. Un-
like Doxorubicin and Cisplatin, Methotrexate can only eliminate cancer cells during





cytotoxic effect to account for this phenomenon, as modeled in [211]. Here, f de-
notes the fraction of cells in the vulnerable phase of the cell cycle for Methotrexate,
a denotes cell cycle time in days, and τ is defined to be minimum(T, fa) with T
being drug exposure time in days.
Besides its direct role in targeting tumor cells, Cisplatin has also been reported
to increase cytotoxic cells’ cancer killing capability up regulating MHC-1 expression
of cancer cells [81, 214, 217, 218]. We also use saturation term to describe this effect,
as it is very likely that high concentration of Cisplatin can also plauteau at up-
regulating MHC-1 in cancer cells. We make the assumption that the concentration
of Cisplatin at which this effect slows down is about the same concentration at
which the cancer killing effect of Cisplatin slows down, so we use the same drug











δCIγ [Iγ] + δC + δCTc
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where δCTcA3 represents the effect of Cisplatin to promote cytotoxic cell’s cancer
killing ability; KC is rate of chemotherapy-induced tumor death; and β1, β2, β3 are
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medicine efficacy coefficients of Methotrexate, Doxorubicin, Cisplatin, respectively.
A description of every chemotherapy-related parameter in our model is given in
Table A.1.
Necrotic cells
As a proportion of cancer cells killed by chemotherapy drugs become necrotic
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(1 − e−β1A1) +KC(1 − e−β2A2)
+KC(1 − e−β3A3)
)
[C]− δN [N ] (5.2)
where αNCA is the fraction of dying cancer cells induced by chemotherapy that turn
into necrotic cells.
Immune cells
Since chemotherapy does not only eliminate tumor cells but also kills immune
cells, we include the effects of chemotherapy in the equations of immune cells as
well. Similar to [216], we assume that the same amount of chemotherapy drugs
is required to affect cancer cells and immune cells, even when the rate at which
chemotherapy kills cancer cells is different than when it kills immune cells. Hence,
we use the same drug efficacy coefficients for cancer and immune cells, but different
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whereKMN , KM , KTN , KTh , KTr , KTc , KDN andKD are the rate of chemotherapy-
induced cell death of naive macrophages, macrophages, naive T cells, helper T cells,
regulatory T cells, cytotoxic cells, naive dendritic cells and dendritic cells, respec-
tively.
Chemotherapy drugs
Chemotherapy drugs are given through IV infusion in osteosarcoma treatments,
so their bioavailability is 100%. Thus, we use the following equations to model the
change in concentration of each chemotherapy drug at the tumor site over time:
d[A1]
dt
= vA1(t)− δA1 [A1] (5.11)
d[A2]
dt
= vA2(t)− δA2 [A2] (5.12)
d[A3]
dt
= vA3(t)− δA3 [A3] (5.13)
Here, vA1(t), vA2(t) and vA3(t) are the amount of Methotrexate, Doxorubicin and
Cisplatin injected per day per liter of body volume, with the unit of mg/l per day;
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while δA1 , δA2 and δA3 are respectively the decay rate of Methotrexate, Doxorubicin
and Cisplatin.
5.1.2 Data of the Model
The populations of cancer cells, necrotic cells, immune cells and cytokines are
obtained from the previous chapter. Then, given a treatment regimen of interest,
we apply its standard dosage to our model. Most doses of chemotherapy drugs
for osteosarcoma are measured in mg/m2, but we model the drug concentration at
tumor site in mg per liter of body volume. We therefore need to convert drug doses
from mg/m2 to mg/l. We use an average body surface area of a human male of 1.9
m2 [219] and an average male body volume of 59.7 liters [220] for conversion. That







= 2.3869 mg/l (5.14)
5.1.3 Parameter values
The drug efficacy coefficients, as well as cell cycle time and fraction of cells in the
vulnerable phase of the cell cycle are taken from [211]. Using the molecular mass of
chemotherapy drugs [216, 221, 223, 222], we convert the drug efficacy coefficients














































Drug efficacy coefficients for Doxorubicin-resistant and Cisplatin-resistant cells
are also included in [211], and can be converted in a similar way. The values for
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all chemotherapy-related parameters in our model and their sources are given in
Table A.1.
The fractional cancer cell killed by chemotherapy, KC , is taken from [216, 224]
to be 0.9, based on the notion that chemotherapy strength is one log kill [225].
Since chemotherapy is more effective at eliminating fast proliferating cells, it is
safe to assume that the rates of chemotherapy-induced death of immune cells are
smaller than that of cancer cells. Hence, KMN , KM , KTN , KTh , KTr , KTc , KDN and
KD are assumed to be smaller than but on the same order of magnitude as KC ,
and we use a value of 0.6 for them, similar to [224].
Decay rates of chemotherapy drugs are derived from their elimination half lives
in the following way:
δA =
ln2
half life of A in days
(5.15)
where δA is the decay rate of A. On average, the elimination half lives of Doxoru-
bicin, Cisplatin and high dose Methotrexate are 2 hours, 25 minutes and 11.5 hours
respectively [226, 227, 228], resulting in the corresponding decay rates of 8.3178,
39.9253 and 1.4466.
As no values for αNCA and δCTcA3 can be found in literature, we assume biolog-
ically reasonable values for these parameters. αNCA is the fraction of dying cancer
cells induced by chemotherapy that become necrotic cells, so it is bounded between
0 and 1. We make the assumption that a large proportion of dying cancer cells from
treatment turn into necrotic cells, and set αNCA = 0.8. For δCTcA3 , we assume that
Cisplatin at maximum effect can double the cancer killing ability of cytotoxic cells,
or equivalently δCTcA3 = 1. In order to investigate whether our assumptions on
these parameters have a large impact on the cancer population, in the later section
we perform sensitivity analysis, as well as study the change in cancer population
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after treatment while varying these two parameters.
Table 5.2: Chemotherapy Parameters. Name, unit, de-
scription, value and source of chemotherapy-related pa-
rameters used in the model.
Parameter Unit Description Value Source
f none
Initial fraction of cells in vulnerable
phase of the cell cycle
0.5 [211]
a day Cell cycle time 0.6667 [211]
T day Duration of drug exposure
τ day min(T, fa) [211]
β1 mg/l
−1 Methotrexate efficacy coefficient 2.4780 [211]
β2 mg/l
−1 Doxorubicin efficacy coefficient 1.8328 [211]
β3 mg/l
−1 Cisplatin efficacy coefficient 0.1467 [211]
KC day
−1
Rate of chemo-induced tumor death 0.9 [216, 224]
KMN day
−1































Rate of chemo-induced death








Effect of Cisplatin to promote cancer
killing ability of cytotoxic cells
1 Assumed
αNCA none
Fraction of chemo-induced dying tumor
cells that become necrotic cells
0.8 Assumed
δA1 day
−1 Decay rate of Methotrexate 1.4466 [228]
δA2 day
−1 Decay rate of Doxorubicin 8.3178 [226]
δA3 day
−1 Decay rate of Cisplatin 39.9253 [227]
5.1.4 Non-Dimensionalization
To achieve additional numerical stability, non-dimensionalization of the whole
system is carried out. For each variable X of the original system in chapter 4, its





where X∞ is the steady state value of X given in Table 4.2. For the newly






where A is the dimensional variable, δA is the decay rate of A, and v
∗
A is the amount
of drug A injected on its first injection day of the treatment. Further details on
non-dimensionalization are given in Appendix B.2.
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To solve the non-dimensional system of ordinary differential equations, we use
solve ivp function from Scipy package in python [188], with initial conditions from
a chosen data point of interest in each cluster.
5.1.5 Sensitivity Analysis
We perform local gradient-based sensitivity analysis on all chemotherapy-related
parameters to study their impacts on the outputs of the system. For the non-
dimensional system dX
dt
= F (X, θ, t) with model parameters θ = θ1, ..., θN , the local






As we are mainly interested in how drug-related parameters affect the number
of cancer cells, we calculate sensitivity of treatment parameters with respect to
cancer and total cell population. Since the effects of the treatment does not reach
the steady state, we consider time-dependent sensitivity. That is, we measure
sensitivity of parameters in every time step throughout the treatment and some
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(5.19)










In addition, we also look at the relative sensitivity, which is commonly used in


















The sensitivity varies for different values of the parameters, so we consider a








where the integrals are computed using a numerical technique called sparse grid
points [190, 191].
5.1.6 Optimization of drug dosage
We introduce a framework to find the appropriate dose of a given treatment
regimen for each patient. To find the optimal dosage to achieve a target cancer









subject to 0 ≤ vi ≤ Ui, i = 1, ...,M
Here, v is a vector of length M , denoting the doses of the M drugs in the given
treatment, t is the time of interest at which cancer population is evaluated for
optimization, typically right after treatment or at the time of surgery. Ĉ(v, t) is
the cancer population with drug doses v at time t of interest, and is computed via
our ODE solver. Ctarget is the target cancer population at time t, and is chosen by
the user. As very high doses of chemotherapy are known to induce high toxicity to
the patient, we put an upper bound constraint Ui on the dosage of each drug.
We utilize the least square error to describe the difference between Ĉ(v, t) and
the target cancer population Ctarget. The regularization term κ
∑M
i=1 |vi| is added
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so that we can reach the approximate target cancer population with the smallest
possible drug doses. The higher the regularizaztion parameter κ is, the more the
optimizer focuses on achieving small doses and less on achieving small error between
Ĉ(v, t) and Ctarget.
The optimize.minimize function from Scipy package in python is used to solve
this optimization problem, with the outputs being the optimal doses.
5.2 Results
5.2.1 Dynamics of cancer microenvironment with MAP treatment
Typical treatments for osteosarcoma include neoadjuvant chemotherapy, usually
for 10 weeks, then surgery, and adjuvant chemotherapy after the surgery for up to a
year [210]. The most common chemotherapy regimen for osteosarcoma in children
and young adults is the MAP regimen, which is a combination of Doxorubicin,
Cisplatin and high dose Methotrexate [209]. This regimen consists of six 35-day
cycles, where two cycles are applied before surgery and the remaining four are
applied after surgery. In each cycle, 37.5 mg/m2 of Doxorubicin and 60 mg/m2 of
Cisplatin are administered through IV per day on day 1 and 2, and 12000 mg/m2
of Metrotrexate is administered through IV over 4 hours per day on day 22 and
29 [229, 230]. Different infusion schedules have been used for Doxorubicin and
Cisplatin: Doxorubicin can be injected as a bolus or a 4-hour infusion each day, or
a continuous infusion over 48 hours, while Cisplatin can be injected over 2 or 4 hours
each day, or continuously over 72 hours [230]. Here, we study the dynamics of cells
and cytokines populations in large osteosarcoma tumors during neoadjuvant MAP
treatment, which includes two 35-day cycles. In particular, we use the steady state
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values of cells and cytokines in chapter 4 as initial conditions, the typical dosage of
the MAP regimen as the drug inputs, and 4-hour infusions on previously specified
days as the injection schedule for each drug. We set the start of chemotherapy
treatment to be 7 days after biopsy, as it usually takes a few days to receive the
results of the biopsy.
Figure 5.2 shows that for all clusters, cancer populations are reduced signifi-
cantly after two cycles of MAP treatment. It is important to note that the cancer
populations do not reach zero after chemotherapy so cancer cells will start grow-
ing again after chemotherapy. However, the goal of neoadjuvant therapy is not to
eradicate cancer cells completely, but only to reduce the boundaries of the tumor
and to remove any small metastases that have not been detected [231].
Cluster 2 has the highest cancer population at the start of treatment, so natu-
rally cluster 2 also has the highest cancer population left after neoadjuvant therapy.
Interestingly, cluster 1 has approximately the same number of cancer cells as clus-
ter 3 at the start of treatment, but ends up with higher cancer population than
cluster 3 after treatment. This is because in each chemotherapy cycle, there are
a few weeks where no chemotherapy drugs are administered in order to allow the
patient to recover from the drugs’ toxicity, and thus during these few weeks, cancer
cells can start growing again. Cluster 1’s cancer population, which is reported in
chapter 4 to have the highest growth rate in the three clusters, grow more during
the weeks with no drugs given, resulting in higher number of cancer cells after
treatment compared to cluster 3. This observation suggests that we should take
the patient’s cancer growth rate into account when choosing their chemotherapy
dosage.
During the MAP treatment, necrotic cells, dendritic cells and HMGB1 oscillate
between increasing and decreasing in abundance. Since chemotherapy drugs aim
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Figure 5.2. Dynamics with MAP treatment. Behaviors of cells and cy-
tokines in osteosarcoma tumors during the MAP treatment and a
few months after treatment. Initial conditions are large tumors in
each cluster, i.e. the without-treatment steady state values of each
cluster. Drug doses are the typical doses of the MAP regimen. The
different color lines indicate the dynamics of different clusters.
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to kill cancer cells, and a fraction of dying cancer cells become necrotic cells, the
population of necrotic cells increases on the days the drugs are injected and there
are many drug-induced dying cancer cells. However, during the weeks where no
chemotherapy drugs are administered, only drug-free dying cancer cells can become
necrotic cells, and with cancer population being already reduced by the previously
given drugs, the number of drug-free dying cancer cells is small, leading to a decrease
in necrotic cell population.
HMGB1 is mainly produced by necrotic cells, so HMGB1 abundance increases
when necrotic population increases and decreases when necrotic population de-
creases. Meanwhile, dendritic cells are activated largely by HMGB1, so the dy-
namics of dendritic cells share the same trend with the dynamics of HMGB1. That
means both HMGB1 and dendritic cells increase on the days chemotherapy drugs
are administered and decrease on the weeks with no drugs given. An increase in
dendritic cell population right after Doxorubicin [232, 233, 234, 235] and Cisplatin
[81, 82, 214] introduction, as well as a rise in HMGB1 production following Dox-
orubicin [234, 235, 236], has been shown in several studies, which aligns with our
results.
We observe that in general, helper T cells, cytotoxic cells and IFN-γ increase
in population during chemotherapy. There are many studies that report an in-
crease in helper T cells and/or cytotoxic T cells’ abundance due to Doxorubicin
[235, 236, 237, 238, 239, 240], Cisplatin [81, 214, 217, 241] and Methotrexate [242],
and thus support our findings. Especially, Doxorubicin has been known to induce
immunogenic cell death, which leads to the maturation of dendritic cells and ac-
cordingly the activation of helper and cytotoxic T cells [232, 238, 243]. IFN-γ is
produced by helper T cells and cytotoxic cells, thus IFN-γ abundance also increases
as these two cells increase in population during MAP treatment. The increase in
105
IFN-γ level after administration of Doxorubicin and Cisplatin has also been ob-
served in multiple studies [214, 234, 235, 244].
On the other hand, population of macrophages, regulatory T cells, cytokines
groups µ1 and µ2 mainly decrease during MAP treatment. These immune cells
are not affected by the necrotic cell death process caused by chemotherapy, so they
decrease in population during chemotherapy as they are also killed by the drugs. µ1
and µ2 are produced by helper T cells, macrophages and cancer cells. Even though
helper T cell population increases during treatment, macrophages and cancer cell
populations decrease at a greater magnitude, which leads to an overall decrease in
µ1 and µ2 throughout MAP treatment. Several other studies have also reported a
reduction in regulatory T cell number due to Cisplatin [81, 214, 217] and a decrease
in the level of IL-6, which is the main component of µ2, due to Methotrexate and
Doxorubicin [242, 244, 245, 246].
5.2.2 Sensitivity analysis
To study the impact of the newly introduced parameters on the outputs of the
model, we perform local sensitivity analysis on the chemotherapy-related parame-
ters using the non-dimensional system. The initial conditions for sensitivity analysis
are the large tumors in each cluster, which we use without-treatment steady state
values to represent. It is worth noting that the cell cycle time, a, is not included
in this sensitivity analysis, because it is a simple measurement rather than a pa-
rameter that needs to be estimated or fitted to the experimental data. The most
sensitive time-averaged parameters in terms of sensitivity and relative sensitivity
are presented in Figure 5.3.
In all clusters, the initial fraction of cells in the vulnerable phase of the cell
cycle f has the largest impact on cancer population among treatment-related pa-
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SensitivityA Relative sensitivityB C
D
Figure 5.3. Sensitivity of chemotherapy-related parameters. Sub-figure
A shows the local sensitivity of 5 most sensitive treatment-related
parameters with respect to cancer population and total cell popu-
lation. Sub-figure B shows the local relative sensitivity of 5 most
sensitive treatment-related parameters with respect to cancer pop-
ulation and total cell population. Sub-figures C and D display the
cancer population after treatment with different values of αNCA
and δCTcA3 , respectively.
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rameters according to both the sensitivity and relative sensitivity analyses. The
rate of chemotherapy-induced cancer cell death, KC , and the drug efficacy coef-
ficients of Doxorubicin and Cisplatin, β2 and β3, are also sensitive to cancer and
total cell population during treatment. Meanwhile, the drug efficacy coefficient of
Methotrexate, β1, does not seem as sensitive, but the decay rate of Methotrexate
is.
We notice that the parameters whose values are assumed, αNCA and δCTcA3 , do
not have a large effect on the cancer population or total cell population based on the
results of the sensitivity analysis. To further confirm this, we also plot the cancer
population after treatment with different values of these parameters. We choose
αNCA ranging from 0.2 to 1, because it is a fraction and thus is bounded between 0
and 1, and δCTcA3 ranging from 0.2 to 5 times its original value. Figure 5.3C and D
show that varying either of these parameters results in negligible changes to cancer
population after treatment.
5.2.3 Dynamics of cancer microenvironment in chemo-resistant tumors
with MAP treatment
The effectiveness of chemotherapy is highly dependent on the existence of resis-
tant cancer cells. We are interested in studying the change in population of cells and
cytokines when osteosarcoma cells are resistant to one or multiple drugs within the
MAP regimen. As mentioned in section 2, we obtain drug efficacy coefficients from
[211], where these values were estimated to fit the survival data of cancer cells under
different chemotherapy drugs. The same study [211] also includes the estimated
drug efficacy coefficients of Doxorubicin and Cisplatin in Doxorubicin-resistant and
Cisplatin-resistant cancer cells, respectively. Using these parameter values, we plot
the dynamics in osteosarcoma microenvironment during MAP treatment when can-
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cer cells are resistant to either Doxorubicin or Cisplatin, or to both drugs. Since
Methotrexate-resistant cells were not used in [211], and hence no parameter values
are available for them, we do not model the dynamics with Methotrexate-resistant
cells.
Figure 5.4A shows that MAP treatment is not as effective in shrinking the tu-
mor, when cancer cells are resistant to Doxorubicin, with the cancer population
after treatment about 60% to 70% higher in Doxorubicin-resistant cells than in
non-Doxorubicin-resistant cells (Table 5.3). The smaller reduction in cancer popu-
lation of Doxorubicin-resistant cells during Doxorubicin administration means fewer
necrotic cells are produced in the process, and accordingly lower level of dendritic
cells (Figure 5.4A), as necrotic cells indirectly promote dendritic cell maturation
through the release of HMGB1. We notice no clear difference in the dynamics of
T cells and macrophages compared to the microenvironment of non-Doxorubicin-
resistant cells. It is worth noting that we model only cancer cells to be resistant to
chemotherapy drugs, so immune cells are by design not resistant to these drugs.
Table 5.3: Cancer population after MAP treatment with
chemotherapy-resistant cells.
Cluster Initial cancer Cancer population after treatment
population Chemotherapy Resistant to Resistant to Resistant to
sensitive DOX CDDP DOX + CDDP
1 1.34× 1010 2.44× 109 3.82× 109 2.49× 109 3.89× 109
2 1.6× 1010 2.6× 109 4.32× 109 2.66× 109 4.41× 109
3 1.34× 1010 1.87× 109 3.23× 109 1.92× 109 3.29× 109







Resistant to DOX and CDDP
Figure 5.4. Dynamics in chemotherapy-resistant cells with MAP
treatment. Sub-figures A-C show the dynamics of immune, can-
cer and necrotic cells in osteosarcoma during the MAP treatment
and a few months after treatment when cancer cells are resistant
to Doxorubicin, Cisplatin, and both Doxorubicin and Cisplatin,
respectively.
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the reduction of cancer population compared to non-Cisplatin-resistant cells (Figure
5.4B, Table 5.3). This is due to the fact that Cisplatin’s drug efficacy parameter,
β3, is small compared to Methotrexate and Doxorubicin’s drug efficacy parameters,
resulting in Cisplatin having a rather minor effect on cancer reduction in the MAP
treatment. Hence, the resistance to Doxorubicin matters more than the resistance
to Cisplatin. Since the Cisplatin-resistance does not have a large impact on the
effectiveness of MAP treatment, cancer cells that are resistant to both Doxorubicin
and Cisplatin have similar dynamics to Doxorubicin-resistant cancer cells (Figure
5.4A, C).
5.2.4 Varying treatment start time
We study the effect of delays in the starting time of treatments on the tumors’
responses to the treatments. Since the tumor growth rate depends on tumor size,
we investigate the effects of delaying the chemotherapy treatment in small, medium
and large tumors, separately. Small tumors are chosen as follows: we first choose
the tumor with the smallest cancer population in cluster 1, then find the tumors in
cluster 2 and 3 that have cancer population closest to the chosen tumor in cluster
1. Medium tumors are taken to be the mean values of all patients in each cluster.
For large tumors, we take the without-treatment steady state values. We plot the
dynamics of cancer population in each cluster when chemotherapy is started 1 week,
which we assume is the earliest start time as it takes a few days to obtain biopsy
results, 1 month, 3 months, and 6 months after the initial diagnosis.
Figure 5.5 and Table 5.4 show that in small and medium tumors, the cancer
population after treatment is higher the longer we wait to start the chemotherapy.
Thus, the earlier start of the chemotherapy leads to the better outcomes in these
tumors. On the contrary, cancer population stays the same after treatment in
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Figure 5.5. Dynamics with different start times of MAP treatment.
Sub-figures A-C show the dynamics of cancer population for dif-
ferent MAP treatment’s start times in small, medium, and large
tumors, respectively. In each sub-figure, from left to right: the
treatment starts at 1 week, 1 month, 3 months, and 6 months after
initial diagnosis.
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large tumors regardless of treatment start time. This is because these large tumors
are at their steady states and do not grow more while the patient waits for the
treatment. Then theoretically the treatment start time does not matter as much
for tumors at the steady state or close to reaching the steady state. However, in
reality, when tumors are large, the functionality of the cancerous body part is likely
compromised, and the quality of the patient’s life is affected, which makes us want
to start the chemotherapy promptly for large tumors.
Table 5.4: Cancer population after MAP treatment with
different treatment start times.
Tumor Cluster Initial cancer Cancer population after treatment
size population Start at Start at Start at Start at
1 week 1 month 3 months 6 months
1 2.7× 108 7.64× 107 9.81× 107 1.82× 108 4.04× 108
Small 2 3.07× 108 6.73× 107 7.76× 107 1.05× 108 1.52× 108
3 1.93× 108 4.29× 107 5.26× 107 8.13× 107 1.31× 108
1 6.9× 109 1.41× 109 1.53× 109 1.81× 109 2.12× 109
Medium 2 6.96× 109 1.27× 109 1.37× 109 1.6× 109 1.9× 109
3 5.05× 109 7.55× 108 8.02× 108 9.19× 108 1.09× 109
1 1.34× 1010 2.44× 109 2.44× 109 2.44× 109 2.44× 109
Large 2 1.6× 1010 2.6× 109 2.6× 109 2.6× 109 2.6× 109
3 1.34× 1010 1.87× 109 1.87× 109 1.87× 109 1.87× 109
It was previously observed in chapter 4 that tumors in cluster 1 grow fast even
when the tumor is small, while tumors in clusters 2 and 3 start growing fast when
the tumor is a bit bigger. Hence, when we delay the treatment for a long time,
the small tumor in cluster 1 grows quickly and ends up with much higher cancer
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population after the treatment than in other clusters, as seen in the treatments
starting at 3 months and 6 months (Figure 5.5A, Table 5.4). For small tumors
in clusters 2 and 3, even though they do grow while waiting for treatment, their
growths are not as fast and their cancer populations after the treatment are still
relatively small with the treatment delay. Therefore, it is important to start the
treatment early for small tumors of cluster 1, and it would be ideal but not as
urgent to start the treatment early for small tumors in clusters 2 and 3.
Figure 5.5B indicates that medium tumors in all three clusters grow comparably
fast, and since their cancer populations after treatment are not very small, we
should start chemotherapy for them as early as possible. We also notice that for
small and medium tumors in all clusters, the difference in cancer population after
the treatment is not significant between starting the treatment after 1 week or 1
month from the diagnosis. However, treatments starting at 3 months or 6 months
result in much bigger cancer population after the treatment. Based on our model,
it is thus not recommended to start the chemotherapy several months after the
diagnosis, but rather to start within a month of the initial diagnosis.
5.2.5 Dynamics of cancer microenvironment with different treatment
regimens
We investigate the effects of two other chemotherapy regimens on the osteosar-
coma microenvironment. A combination of Doxorubicin and Cisplatin (AP) is a
very common treatment of osteosarcoma tumors in older adults, as they are less
likely to be able to tolerate high dose Methotrexate. This regimen consists of three
preoperative 21-day cycles, where 25 mg/m2 of Doxorubicin is given as a bolus
once per day from day 1 to 3, and 100 mg/m2 of Cisplatin is given as a continuous
infusion over 24 hours on day 1 in each cycle [247, 248]. High dose Methotrexate
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A Treatment with DOX and CDDP
Treatment with MTX as single agentB
Figure 5.6. Dynamics with different treatment regimens. Sub-figure A
shows the dynamics of cells and cytokines in osteosarcoma mi-
croenvironment in response to the combination of Doxorubicin and
Cisplatin. Sub-figure B shows the dynamics of cells and cytokines
in osteosarcoma microenvironment in response to a high dose of
Methotrexate as a single agent.
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(MTX) has also been used as a single agent to treat osteosarcoma, with 4 courses of
8 to 12 mg/m2 given weekly before surgery [249]. In this study, we use the average
dose which is 10 mg/m2 of Methotrexate injected over 4 hours on day 1 every week
for this regimen.
Figure 5.6 shows that MTX and AP regimens both have higher cancer popula-
tion after treatment than MAP. This agrees with the finding from [250] that AP
regimen is less effective but safer than MAP regimen. Meanwhile, MTX as a single
agent is reported to be insufficient as a neoadjuvant therapy for osteosarcoma in
[249], which uses the same MTX dosages and schedules as this study. Overall, ac-
cording to our model, MAP is the superior treatment to MTX and AP in terms of
cancer-killing ability. In fact, a recent study reports that MAP is still the favorable
option for osteosarcoma among various combinations of chemotherapy drugs [251].
The AP regimen has relatively similar dynamics of cells and cytokines as the
MAP regimen. That is, the populations of HMGB1, necrotic and dendritic cells
increase when drugs are given and decrease when no drugs are given; while popu-
lations of helper T cells, cytotoxic cells and IFN-γ decrease at a smaller magnitude
than their increase, so in general they increase during treatment; and regulatory
T cells, macrophages, cytokines groups µ1 and µ2 generally decrease in abundance
during treatment. The MTX treatment is given at closer intervals than AP and
MAP treatments, so there is always some drug at the tumor site during MTX
treatment. Therefore, the change in population of cells and cytokines over time
for MTX regimen is smoother and does not fluctuate as much as the other two
treatments, even though the dynamics of MTX regimen follow the same trend as
them.
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5.2.6 Optimal dosage for MAP treatment
Since neoadjuvant chemotherapy tries to reduce the boundaries of the tumor
before surgery, we can choose the desired size of tumor for surgery and run our
optimization framework to find the optimal dosage of chemotherapy drugs for the
tumor to reach this size at a specific time. Osteosarcoma sizes vary greatly be-
tween patients at first diagnosis, and large tumors cannot reduce to the same size
as small tumors after neoadjuvant treatment without exceeding the safe dosage of
chemotherapy drugs. Thus, we choose different desired cancer population to opti-
mize for depending on the size of tumor at first diagnosis. With MAP being the
preferable treatment for osteosarcoma as mentioned in the previous section, here
we present the optimal dosage of the MAP regimen for a large and a small tumor
in each cluster, where the desired cancer population is 2.916× 109 for large tumors
and 1.36 × 108 for small tumors, which is equivalent to about 5cm per dimension
(length, width, depth) for large tumors and 1.8cm per dimension for small tumors.
We use 20000 mg/m2 of Methotrexate, 45 mg/m2 of Doxorubicin, and 75 mg/m2
of Cisplatin per infusion day as maximum potential dosage, or equivalently 40000
mg/m2 of Methotrexate, 90 mg/m2 of Doxorubicin, and 150 mg/m2 of Cisplatin
per 35-day cycle.
Table 5.5: Optimal MAP dosages for large tumors.
Cluster Initial Cancer population MTX DOX CDDP
cancer population after treatment (mg/m2) (mg/m2) (mg/m2)
1 1.34× 1010 2.916× 109 8993 28 45
2 1.6× 1010 2.916× 109 10134 32 51
3 1.34× 1010 2.916× 109 6176 19 31
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Table 5.6: Optimal MAP dosages for small tumors.
Cluster Initial Cancer population MTX DOX CDDP
cancer population after treatment (mg/m2) (mg/m2) (mg/m2)
1 2.7× 108 1.36× 108 4926 15 25
2 3.07× 108 1.36× 108 4196 13 21
3 1.93× 108 1.36× 108 1305 3 6
The optimal dosages for large tumors are given in Table 5.5. Large tumors are
taken to be the steady state values of each cluster. As cluster 2 has the highest
cancer population at the steady state, it has the highest optimal dosage for each
drug of the MAP treatment among all clusters. Interestingly, cluster 1 and 3 have
the same cancer population before treatment, but cluster 1 needs higher dosage to
achieve the same cancer population after treatment as cluster 3. This is due to the
fact that cluster 1’s cancer cells grow faster during treatment, so the same dosage
of drugs would result in higher cancer population in cluster 1 than in cluster 3 after
treatment, as seen in section 3.1. Thus, it is important to take tumor growth rate
of the patient into account while finding the optimal dosage of chemotherapy.
Figure 5.7A shows that cancer cells in cluster 1 also grow fast after treatment,
so it would be ideal to perform surgery quickly after neoadjuvant therapy. If it is
impossible to start surgery promptly, we can choose a later time point to optimize
for, so that at the time of surgery we still have the desired tumor size for resection.
For example, if we cannot perform surgery until a month after chemotherapy, in-
stead of using cancer population at day 80 for optimization, which is 3 days after
the second cycle of chemotherapy, we can use cancer population at day 107 for
optimization to find optimal dosage, which is 30 days after the second cycle of
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Figure 5.7. Dynamics with optimal dosages for MAP treatment. Sub-
figure A shows the dynamics of cancer population in a large tu-
mor in each cluster, where MAP dosages were optimized to obtain
2.916 × 109 cancer cells after treatment. Sub-figure B shows the
dynamics of cancer population in a small tumor in each cluster,
where MAP dosages were optimized to obtain 1.36 × 108 cancer
cells after treatment.
chemotherapy. Then with the estimated optimal dosage, we will have the desired
cancer population at day 107, which is the time of surgery.
The optimal dosages for a small tumor in each cluster are given in Table 5.6.
Small tumors are chosen in the same method as described in section 5.2.4. The
cancer populations in these small tumors are not much bigger than the desired
cancer population after treatment, so in all clusters the optimal dosages for small
tumors are much smaller than the optimal dosages for large tumors. Especially
cluster 3, with cancer population before treatment very close to desired cancer
population, has very small optimal dosages.
In many cases, even though the tumor is small enough for resection, neoadju-
vant chemotherapy is still given to remove any potential metastases that are too
small to be yet detected. Another reason for neoadjuvant chemotherapy in small
tumors is to allow evaluation of the tumor response [209]. Figure 5.7B suggests
that although chemotherapy does not reduce cancer populations significantly as
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the cancer populations are already small to begin with, it helps prevent the cancer
populations from growing bigger before surgery. Therefore, chemotherapy can also
be used to control the growth of tumor while the patient waits for surgery.
Overall, with our optimization framework, we can find the optimal chemother-
apy dosage to obtain the desired cancer population on the day of surgery. Our re-
sults show that it is important to consider each individual patient’s cancer growth
rate while computing optimal dosage, as patients with faster growth rate would
need a higher dose.
5.3 Discussion
Our results indicate that besides reducing the number of cancer cells, chemother-
apy induces specific behaviors in certain immune cells and cytokines by causing
necrosis of cancer cells. In particular, the population of HMGB1 and dendritic
cells increase when chemotherapy drugs are administered and decrease when these
drugs are not given. In addition, helper T cells, cytotoxic cells and IFN-γ gener-
ally increase in population during treatment, which aligns with the findings from
[81, 82, 214, 217, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 244]. Mean-
while, cells and cytokines that are not affected by this necrotic cell death, decrease
in abundance due to being killed by chemotherapy drugs.
We note that it would be good to start chemotherapy early, unless the tumor is
close to its steady state, as tumors of small and medium size will grow more while
the patient waits for treatment. It is especially important to start chemotherapy
promptly for tumors that grow fast such as those in cluster 1. Interestingly, we also
notice that with the same initial cancer population and the same dosage, the cancer
population after treatment is higher in cluster 1 than in cluster 3, where cluster
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3 has slower cancer growth rate than cluster 1. All of these observations suggest
that it is necessary to take the unique growth rate of the tumor into consideration
when choosing the dosage and treatment start time for the patient, inferring the
importance of personalized medicine.
In this study, we introduced a simple optimization framework to find the appro-
priate drug dosages to achieve a desired cancer population on a chosen day, such
as the day of surgery. The results of our optimization also agrees with the above
observation that the individual’s cancer growth rate is essential for calculating op-
timal chemotherapy dosages. Since high doses of chemotherapy are known to have
high toxicity and to induce many serious health problems [252, 253], it could be
useful to use a mathematical model such as ours to estimate the appropriate dose
rather than to give the standard dose to all tumor sizes, especially when small tu-
mors are likely to need much smaller doses than the standard ones. Moreover, our
model divides patients into groups based on their immune compositions, and thus
can estimate their cancer growth more accurately than having one model for all
patients, resulting in a more customized dosage recommendation for each patient.
Finding the right parameter values is a big challenge in mathematical modelling
of cancers. While it would be ideal to acquire parameters by performing in vivo and
in vitro experiments, these experiments are often expensive and time-consuming.
Here, we use most chemotherapy-related parameters from a study that fitted these
values to experimental data [211]. Therefore, our treatment parameters should be
close to parameter values obtained by performing experiments, and more accurate
than values chosen based on biological rationality or derived from assumptions. For
the two parameters that we have to assume appropriate values for, we study their
impact on the results through sensitivity analysis as well as by varying them, and
find that different values of these parameters result in fairly similar outputs of our
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model.
There are still some factors that our model does not account for. For instance,
there are multiple levels of sensitivity of cancer cells to chemotherapy, which means
two different patients can both be resistant to a chemotherapy drug, but one pa-
tient might be more sensitive than the other. Thus, the drug efficacy coefficient
of Doxorubicin-/Cisplatin-resistant cells used in our model do not represent all
Doxorubicin-/Cisplatin-resistant drug efficacies, as these parameters vary based
on the level of resistance of the cells. However, our model is still useful for dose
recommendations or for physicians to take into consideration while choosing be-
tween treatment options. Based on our model, a physician can monitor the tumor
reduction throughout the treatment and adjust parameters such as drug efficacy
coefficients according to how the tumor responds to treatment.
Another factor that our model did not consider is the different rates of drug-
induced immune cell death. Since chemotherapy target cells with a faster metabolic
rate more successfully [216], it is reasonable to expect that the death rates by
chemotherapy differ between types of immune cells. Therefore, one idea to better
our model is to update the rates of chemotherapy-induced death of immune cells
in proportion to their metabolic rates. Other ways to improve upon this work
include adding other chemotherapy drugs like Ifosfamide, which is also a commonly
used drug for osteosarcoma [209, 210]; extending to a different treatment option
besides chemotherapy such as radiotherapy and immunotherapy; or using partial
differential equations to take into account the spatial distribution of the tumors as
well.
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C H A P T E R 6
CONCLUSION
Due to the high cost of flow and mass cytometry, there has been a recent surge in
the development of computational methods for estimating the relative distributions
of cell types from the gene expression profile of a bulk of cells. These computational
methods are referred to as digital cytometry methods. In chapter 2, we compare
five common digital cytometry methods, including three linear models and two
rank-based methods, on simulation data, whole blood RNA-Seq data, and PBMC
microarray data.
Rank-based methods ssGSEA DM and SingScore DM give conflicting results
between sample-level and cell-level correlation with ground truth fractions, and
overall perform worse than linear methods. DeconRNASeq’s performance depends
heavily on how comparable the signature matrix and mixture data are. CIBER-
SORT and CIBERSORTx B-mode perform the best among all mentioned methods
based on sample-level and cell-level Pearson and Spearman correlation with ground
truth cell fractions for all three data sets, regardless of the signature matrix used.
CIBERSORTx B-mode, which uses batch correction on the mixture data, tends to
slightly outperform CIBERSORT, especially when signature matrix and mixture
data come from different platforms. However, CIBERSORTx S-mode, which uses
batch correction on the signature matrix, does not perform as well. This suggests
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further investigation into the way batch correction is used for adjusting the signa-
ture matrix in order to eliminate the technical variations between signature matrix
and mixture data.
As the tumor immune microenvironment has been shown to be important in
predicting the tumor progression and the outcome of treatments, in chapter 3,
we study different immune patterns in osteosarcoma and their clinical character-
istics. We use the best performing digital cytometry method reported in chapter
2, CIBERSORTx B-mode, to obtain the relative abundance of 22 immune cells in
osteosarcoma primary tumors. Then we cluster patients based on their estimated
immune abundance and analyze the characteristics of these clusters, along with the
relationship between immune infiltration and outcome of patients.
Three clusters of osteosarcoma patients with distinct immune compositions
are found. We observe that abundance of cytotoxic T cells, NK cells and M1
Macrophages have a positive association with prognosis, while abundance of γδ
T cells, Mast cells, M0 Macrophages and Dendritic cells have a negative associ-
ation with prognosis. Accordingly, cluster 2, with the highest proportion of M0
macrophages and the lowest proportion of cytotoxic T cells and M1 macrophages,
has the worst outcome among clusters. Cluster 3, with higher levels of cytotoxic T
cells, M1 macrophages and lower level of M0 macrophages than cluster 2, appears
to have the best outcome. Cluster 1, which has both high levels of immune cells
with good prognosis and of immune cells with poor prognosis, has better outcome
than cluster 2 but worse outcome than cluster 3.
Using the same cluster assignment as chapter 3, in chapter 4, we build a data-
driven mathematical model of osteosarcoma progression while taking into account
the interactions between immune cells and cancer cells. Based on our model, out of
the three clusters, cluster 3 appears to have the most favorable tumor growth, and
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cluster 2 has the least favorable growth. This observation agrees with the findings
from clinical information of these clusters in chapter 3, as mentioned above. We
also find that during osteosarcoma progression, the number of dendritic cells, helper
T cells, cytotoxic cells, and the amount of IFN-γ first increase and then decrease,
while the regulatory T cell population decreases and then increases. This switch in
the dynamics of immune cells and cytokines happens around the same time that
cancer cells have the fastest growth.
The global sensitivity analysis in chapter 4 indicates that the cancer death rates
by cytotoxic cells and IFN-γ, the cancer proliferation rates by cytokines groups µ1
and µ2, as well as the cancer self-proliferation and apoptosis rates are the most
impactful parameters on cancer growth. Additionally, among all immune param-
eters, the activation and decay rates of macrophages and regulatory T cells have
the most impact on cancer growth. The results of chapter 4 also suggest that it is
necessary to investigate the complex interactions between immune cells and cancer
cells instead of purely looking at the abundance of certain immune cells as a marker
for the disease’s progression.
In chapter 5, we extend the model in chapter 4 to include the interactions be-
tween the key components of osteosarcoma microenvironment and common chemother-
apy drugs: Methotrexate, Doxorubicin and Cisplatin. We find that during the
chemotherapy treatment, dendritic cells and HMGB1 increase in population when
drugs are given and decrease in population while the patient waits for the next dose
of drugs, while helper T cells, cytotoxic cells and IFN-γ have an overall increase in
abundance. Other cells and cytokines of the microenvironment, which are not un-
der the impact of necrotic cell death, have reduced populations after the treatment.
Overall, the MAP regimen, which consists of all three drugs above, is effective at
minimizing the number of cancer cells, and works better than Methotrexate alone
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or a combination of Doxorubicin and Cisplatin.
We observe that it is important to start chemotherapy treatment quickly after
diagnosis, unless the tumor is close to its steady state, as the tumor can grow while
the patient waits for treatments. Interestingly, with the same dosage and treatment
start time, tumors in cluster 1 have a higher cancer population after treatment than
those in cluster 3, because cluster 1’s tumors have a faster growth rate. Accordingly,
tumors in cluster 1 need higher dosages to achieve the same results as tumors in
cluster 3. These findings from chapter 5 highlight the importance of considering the
individual growth of the tumor when deciding on the dosage and treatment start
time for a patient, as fast growing tumors require higher dosages and an earlier
start to treatment than slow growing tumors.
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A P P E N D I X A
SUPPORTING INFORMATION FOR CHAPTER 4
A.1 System Analysis
A.1.1 Full dimensional system of ODEs





λMIγ [Iγ] + λMµ1 [µ1]
)





λMIγ [Iγ] + λMµ1 [µ1]
)
[MN ]− δM [M ] , (A.2)
d [TN ]
dt
= ATN − (λThM [M ] + λThD [D]) [TN ]
− λTrµ1 [µ1] [TN ]
− (λTcTh [Th] + λTcM [M ] + λTcD [D]) [TN ]− δTN [TN ] , (A.3)
d [Th]
dt
= (λThM [M ] + λThD [D]) [TN ]− (δThTr [Tr] + δThµ1 [µ1] + δTh) [Th] , (A.4)
d [Tr]
dt
= (λTrµ1 [µ1]) [TN ]− δTr [Tr] , (A.5)
d [Tc]
dt
= (λTcTh [Th] + λTcM [M ] + λTcD [D]) [TN ]
− (δTcTr [Tr] + δTcµ1 [µ1] + δTc) [Tc] , (A.6)
d [DN ]
dt
= ADN − (λDC [C] + λDH [H]) [DN ]− δDN [DN ] , (A.7)
d [D]
dt


















δCTc [Tc] + δCIγ [Iγ] + δC
)
[C]− δN [N ] , (A.10)
d [Iγ]
dt
= λIγTh [Th] + λIγTc [Tc]− δIγ [Iγ] , (A.11)
d [µ1]
dt
= λµ1Th [Th] + λµ1M [M ] + λµ1C [C]− δµ1 [µ1] , (A.12)
d [µ2]
dt
= λµ2Th [Th] + λµ2M [M ] + λµ2C [C]− δµ2 [µ2] , (A.13)
d [H]
dt
= λHM [M ] + λHD [D] + λHN [N ]− δH [H] . (A.14)
A.1.2 Proof of positivity
To prove that the system with positive coefficients and positive initial condi-
tions has a positive solution, let us consider the set of integrating factors, one for
each variable:




λMIγ [Iγ] + λMµ1 [µ1] + δMN
)
ds
ηTN (t) = exp
t∫
0
(λThM [M ] + λThD [D] + λTrµ1 [µ1]
+λTcTh [Th] + λTcM [M ] + λTcD [D] + δTN ) ds
ηTh (t) = exp
t∫
0
(δThTr [Tr] + δThµ1 [µ1] + δTh) ds
ηTC (t) = exp
t∫
0
(δTcTr [Tr] + δTcµ1 [µ1] + δTc) ds
ηDN (t) = exp
t∫
0
(λDC [C] + λDH [H] + δDN ) ds
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ηD (t) = exp
t∫
0
(δDC [C] + δD) ds










ηM (t) = exp (δM t) , ηTr (t) = exp (δTrt) , ηN (t) = exp (δN t) , ηH (t) = exp (δHt) ,




, ηµ1 (t) = exp (δµ1t) , ηµ2 (t) = exp (δµ2t) .
These integrating factors will not allow us to derive explicit solution as some of
them are defined through the unknown variables. However, it is important to note
that the factors are strictly positive and allow us to rewrite the system as:
d ([MN ] ηMN )
dt
= AMNηMN ,




λMIγ [Iγ] + λMµ1 [µ1]
)
[MN ] ηM ,





= (λThM [M ] + λThD [D]) [TN ] ηTh ,
d ([Tr] ηTr)
dt
= (λTrµ1 [µ1]) [TN ] ηTr ,
d ([Tc] ηTc)
dt
= (λTcTh [Th] + λTcM [M ] + λTcD [D]) [TN ] ηTc ,




























= (λµ1Th [Th] + λµ1M [M ] + λµ1C [C]) ηµ1 ,
d ([µ2] ηµ2)
dt




= (λHM [M ] + λHD [D] + λHN [N ]) ηH .
We see that the right-hand side of each equation in this system is non-negative,
which means that the variable-factor product ([X] ηX) is non-decreasing for each
variable [X], and thus, if positive, initially remains positive at all times. Since the
integrating factor is positive by design, the positivity of the variables follows.
A.1.3 Proof of boundedness
Macrophages
Adding Equations (A.1) and (A.2), we obtain
d ([MN ] + [M ])
dt
= AMN−δMN [MN ]−δM [M ] ≤ AMN−min (δMN , δM) ([MN ] + [M ]) .
Thus, integrating, we obtain
[MN ] + [M ] ≤
AMN
min (δMN , δM)
(
1− e−min(δMN , δM)t
)
+ e−min(δMN , δM)t ([MN ] (0) + [M ] (0)) .
Since the right-hand side is bounded and each variable is positive, this proves
that each variable is bounded.
T-cells
Adding Equations (A.3)–(A.6) and using the positivity of all variables, we ob-
tain
d ([TN ] + [Th] + [Tr] + [Tc])
dt
=ATN − δTN [TN ]− δTr [Tr]
− (δThTr [Tr] + δThµ1 [µ1] + δTh) [Th]
− (δTcTr [Tr] + δTcµ1 [µ1] + δTc) [Tc]
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≤ATN −min (δTN , δTh , δTc , δTr) ([TN ] + [Th] + [Tr] + [Tc]) .
Then, integrating, we obtain
[TN ] + [Th] + [Tr] + [Tc] ≤
ATN
min (δTN , δTh , δTc , δTr)
(
1− e−min(δTN , δTh , δTc , δTr)t
)
+ e−min(δTN , δTh , δTc , δTr)t ([TN ] (0) + [Th] (0) + [Tr] (0) + [Tc] (0)) .
Since the right-hand side is bounded and each variable is positive, this proves
that each variable is bounded.
Dendritic cells
Adding Equations (A.7) and (A.8) and using the positivity of [C], we obtain
d ([DN ] + [D])
dt
=ADN − δDN [DN ]− (δDC [C] + δD) [D]
≤ADN −min (δDN , δD) ([DN ] + [D]) .
Similar to the previous cases, integrated bound
[DN ]+[D] ≤
ADN
min (δDN , δD)
(
1− e−min(δDN , δD)t
)
+emin(δDN , δD)t ([DN ] (0) + [D] (0))
proves the upper bound on [DN ] and [D].
Cancer cells









δCTc [Tc] + δCIγ [Iγ] + δC
)
[C] ≤ 0.
Integrating the inequality with implicit dependence on [C] , [µ1] , and [µ2], we
obtain











Since [C] , [µ1] , and [µ2] are proven to be positive, the right-hand side is
bounded and, thus, [C] is bounded.
Interferon-γ
We require the bound on interferon before proving the bound on necrotic cells.
Since [Th] and [Tc] are proven to be bounded, we could claim that
λIγTh [Th] + λIγTc [Tc] ≤ λmaxIγ .
This, together with Equation (A.11), yields the following inequality:
d [Iγ]
dt
+ δIγ [Iγ] ≤ λmaxIγ ,







+ e−δIγ t [Iγ] (0) .
Remaining variables
For each of the remaining variables, the bounds proven above result in the upper
bounds for the positive parts of the right-hand side in each equation as follows
αNC
(
δCTc [Tc] + δCIγ [Iγ] + δC
)
[C] ≤λmaxN ,
λµ1Th [Th] + λµ1M [M ] + λµ1C [C] ≤λmaxµ1 ,
λµ2Th [Th] + λµ2M [M ] + λµ2C [C] ≤λmaxµ2 ,
λHM [M ] + λHD [D] + λHN [N ] ≤λmaxH .








+ δµ1 [µ1] ≤λmaxµ1 ,
d [µ2]
dt
+ δµ2 [µ2] ≤λmaxµ2 ,
d [H]
dt































+ e−δH t [H] (0) ,
thus, proving the upper bounds.
A.2 Derivation of the parameter set
A.2.1 Assumptions on parameters
We adopt natural degradation/decay rates of immune cells and cytokines based
on information about their half life from the literature (see Table A.1). For example,
the degradation/decay rate of X is calculated as:
δX =
ln2
half life of X in days
The decay rate of µ1 is estimated to be a weighted average of the decay rates of
cytokines within µ1, where the weights are proportional to the abundance of these
cytokines. A similar procedure is carried out for µ2. The obtained natural decay
rates are as follows:
δMN = 0.693, δM = 0.015, δO = 1.219, δTN = 0.00042,
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δTh = 0.231, δTr = 0.063, δTc = 0.406, δDN = 1.664,
δD = 0.277, δIγ = 33.27, δµ1 = 487.48, δµ2 = 5.15,
δH = 58.7
For the proliferation rate of tumor cells, we gathered information on osteosar-
coma growth in humans. A study reported that the mean exponential growth
constant of primary osteosarcoma tumors was between 0.0054 and 0.02784 [254].
We took the average of these values and chose λC = 0.01662. Then, we made the
assumption that the proliferation rate of cancer cells themselves was 20 times larger




µ2 consists of IL-6, which is a major pro-tumor cytokine; therefore, we assume






or equivalently, λC = 40λCµ1µ
mean
1 (A.16)
We also assume that cytotoxic cells kill tumor cells twice as fast as IFN-γ, and
IFN-γ is 10-times more effective at killing cancer cells compared with the cancer
cell natural death rate:
δCIγI
mean







c = 20δC (A.18)
Since M1 and M2 macrophages are activated solely by IFN-γ and µ1, respec-
tively, we assume that the ratio of macrophages activated by IFN-γ to macrophages












We make the assumption that helper T cells are predominantly activated by
antigen presenting dendritic cells and that the inhibition of helper T cells by regu-








1 = 20δTh (A.21)
We also assume that the activation of cytotoxic cells by dendritic cells (both
through antigen presentation and IL-12) is twice as effective compared with acti-







while the inhibition of cytotoxic cells by regulatory T cells and by µ1 are each





1 = 20δTc (A.23)
For dendritic cells, we make the assumption that activation by HMGB1 is twice
as effective compared with activation by cancer cells and that the inhibition by





mean = δD (A.25)






















Lastly, we assume that αNC = 3/4 and that carrying capacity of cancer is twice
the steady state value of cancer, that is C0 = 2C
∞.
A.2.2 Parameter values and sources
Table A.1: Non-dimensional parameter values for each
cluster.
Parameter Cluster 1 Cluster 2 Cluster 3 Source
λMIγ 4.3649× 10−3 8.4234× 10−4 2.8083× 10−3 Estimated
λMµ1 1.0635× 10−2 1.4158× 10−2 1.2192× 10−2 Estimated
λThM 3.3434× 10−2 1.9270× 10−2 2.2194× 10−2 Estimated
λThD 1.0963× 10 7.3778 9.8325 Estimated
λTrµ1 6.3× 10−2 6.3× 10−2 6.3× 10−2 Estimated
λTcTh 6.1171 2.3846 2.8415 Estimated
λTcM 1.7478 1.2263 1.4683 Estimated
λTcD 1.1463× 10 9.3900 1.3011× 10 Estimated
λDC 4.0114× 10−1 4.8942× 10−1 5.9472× 10−1 Estimated
λDH 4.1518× 10−1 4.2621× 10−1 4.1729× 10−1 Estimated
λC 1.662× 10−2 1.662× 10−2 1.662× 10−2 [254]
λCµ1 3.7101× 10−4 3.5910× 10−4 4.0692× 10−4 Estimated
λCµ2 7.1405× 10−4 6.3207× 10−4 5.7910× 10−4 Estimated
λIγTh 6.3095 1.1946× 10 4.1848 Estimated
λIγTc 2.6961× 10 2.1324× 10 2.9085× 10 Estimated
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λµ1Th 1.8813× 102 1.1491× 102 1.0315× 102 Estimated
λµ1M 1.0751× 102 1.1818× 102 1.0661× 102 Estimated
λµ1C 1.9184× 102 2.5440× 102 2.7772× 102 Estimated
λµ2Th 1.2313 6.8806× 10−1 6.0936× 10−1 Estimated
λµ2M 1.4073 1.4153 1.2595 Estimated
λµ2C 2.5113 3.0467 3.2811 Estimated
λHM 4.4046 5.8355 1.8254 Estimated
λHD 3.6107 5.5856 2.0218 Estimated
λHN 5.0685× 10 4.7279× 10 5.4853× 10 Estimated
δMN 6.93× 10−1 6.93× 10−1 6.93× 10−1 [255, 256, 257]
δM 1.5× 10−2 1.5× 10−2 1.5× 10−2 [258, 259]
δTN 4.2× 10−4 4.2× 10−4 4.2× 10−4 [260]
δThTr 6.6404 3.1732 5.0991 Estimated
δThµ1 4.1253 3.9929 4.5246 Estimated
δTh 2.31× 10−1 2.31× 10−1 2.31× 10−1 [261]
δTr 6.3× 10−2 6.3× 10−2 6.3× 10−2 [262]
δTcTr 1.1671× 10 5.5771 8.9620 Estimated
δTcµ1 7.2505 7.0179 7.9524 Estimated
δTc 4.06× 10−1 4.06× 10−1 4.06× 10−1 [261]
δDN 1.664 1.664 1.664 [263]
δDC 5.3932× 10−1 6.3864× 10−1 7.3501× 10−1 Estimated
δD 2.77× 10−1 2.77× 10−1 2.77× 10−1 [264]
δCTc 1.2269× 10−2 9.6574× 10−3 8.4017× 10−3 Estimated
δCIγ 4.5923× 10−3 6.4192× 10−3 8.4660× 10−3 Estimated
δC 3.0078× 10−4 1.0390× 10−3 2.4530× 10−4 Estimated
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δN 4.5935× 10−1 4.8360× 10−1 1.1137× 10−1 Estimated
δIγ 3.327× 10 3.327× 10 3.327× 10 [265]
δµ1 4.8748× 102 4.8748× 102 4.8748× 102 [266, 267, 268, 269]
δµ2 5.15 5.15 5.15 [270, 271]
δH 5.87× 10 5.87× 10 5.87× 10 [272]
AMN 7.4055× 10−1 7.0151× 10−1 7.1382× 10−1 Estimated
ATN 1.0581× 102 1.7917 3.1561 Estimated
ADN 3.3325 2.3958 2.4867 Estimated
αMNM 3.1701 5.6721× 10−1 1.3878 Scaling factor
αTNTh 1.4396 1.8848× 10−1 8.8053× 10−2 Scaling factor
αTNTr 7.4588× 10−1 8.2864× 10−2 1.0267× 10−1 Scaling factor
αTNTc 4.6531 3.0144× 10−2 1.3172× 10−1 Scaling factor
αDND 2.0440 7.9922× 10−1 8.1299× 10−1 Scaling factor
A.3 Non-Dimensionalization































































































































































































































































































































































































































































































r , δThµ1 = δThµ1µ
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1 , δDC = δDCC
















































































































A P P E N D I X B
SUPPORTING INFORMATION FOR CHAPTER 5
B.1 Full dimensional system of ODEs






λMIγ [Iγ] + λMµ1 [µ1]
)












(1 − e−β1A1) +KMN (1 − e−β2A2)







λMIγ [Iγ] + λMµ1 [µ1]
)
















= ATN − (λThM [M ] + λThD [D]) [TN ]− λTrµ1 [µ1] [TN ]












(1 − e−β1A1) +KTN (1 − e−β2A2)







































































(1 − e−β1A1) +KDN (1 − e−β2A2)






























δCIγ [Iγ] + δC + δCTc
(

























δCIγ [Iγ] + δC + δCTc
(
















(1 − e−β1A1) +KC(1 − e−β2A2)
+KC(1 − e−β3A3)
)
[C]− δN [N ] (B.10)
d [Iγ]
dt
= λIγTh [Th] + λIγTc [Tc]− δIγ [Iγ] (B.11)
d [µ1]
dt
= λµ1Th [Th] + λµ1M [M ] + λµ1C [C]− δµ1 [µ1] (B.12)
d [µ2]
dt
= λµ2Th [Th] + λµ2M [M ] + λµ2C [C]− δµ2 [µ2] (B.13)
d [H]
dt
= λHM [M ] + λHD [D] + λHN [N ]− δH [H] (B.14)
d[A1]
dt
= vA1(t) − δA1[A1] (B.15)
d[A2]
dt
= vA2(t) − δA2[A2] (B.16)
d[A3]
dt
= vA3(t) − δA3[A3] (B.17)
B.2 Non-Dimensionalization






































(1 − e−β1A1) +KMN (1 − e−β2A2)
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(1 − e−β1A1) +KTN (1 − e−β2A2)

































































































































































(1 − e−β1A1) +KDN (1 − e−β2A2)








































































+ δC + δCTc
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+ δC + δCTc
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= vA1(t) − δA1[A1] (B.28)
d[A2]
dt
= vA2(t) − δA2[A2] (B.29)
d[A3]
dt
= vA3(t) − δA3[A3] (B.30)
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C., Lebbé, C., Peschel, C., Quirt, I., Clark, J., Wolchok, J., Weber, J., Tian,
J., Yellin, M., Nichol, G., Hoos, A. & Urba, W. Improved Survival with Ip-
ilimumab in Patients with Metastatic Melanoma. New England Journal Of
Medicine. 363, 711-723 (2010).
[150] Tawbi, H., Burgess, M., Bolejack, V., Van Tine, B., Schuetze, S., Hu, J.,
D’Angelo, S., Attia, S., Riedel, R., Priebat, D., Movva, S., Davis, L., Okuno,
S., Reed, D., Crowley, J., Butterfield, L., Salazar, R., Rodriguez-Canales, J.,
Lazar, A., Wistuba, I., Baker, L., Maki, R., Reinke, D. & Patel, S. Pem-
brolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028):
a multicentre, two-cohort, single-arm, open-label, phase 2 trial. The Lancet
Oncology. 18, 1493-1501 (2017).
[151] Thanindratarn, P., Dean, D., Nelson, S., Hornicek, F. & Duan, Z. Advances
in immune checkpoint inhibitors for bone sarcoma therapy. Journal Of Bone
Oncology. 15 pp. 100221 (2019).
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clinical trial of mixed bacterial vaccine (Coley’s toxins) in patients with NY-
ESO-1 expressing cancers: Immunological effects and clinical activity. Clinical
Cancer Research. 18, 5449-5459 (2012).
[156] Ling, Z., Fan, G., Yao, D., Zhao, J., Zhou, Y., Feng, J., Zhou, G. & Chen,
Y. MicroRNA?150 functions as a tumor suppressor and sensitizes osteosar-
coma to doxorubicin?induced apoptosis by targeting RUNX2. Experimental
And Therapeutic Medicine. (2019).
[157] Zhou, Q., Xian, M., Xiang, S., Xiang, D., Shao, X., Wang, J., Cao, J., Yang,
X., Yang, B., Ying, M. & Others All-trans retinoic acid prevents osteosarcoma
metastasis by inhibiting M2 polarization of tumor-associated macrophages.
Cancer Immunology Research. 5, 547-559 (2017).
[158] Kimura, Y. & Sumiyoshi, M. Resveratrol Prevents Tumor Growth and Metas-
tasis by Inhibiting Lymphangiogenesis and M2 Macrophage Activation and
Differentiation in Tumor-associated Macrophages. Nutrition And Cancer. 68,
667-678 (2016).
[159] Kimura, Y. & Sumiyoshi, M. Antitumor and antimetastatic actions of
dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2
macrophage differentiation in tumor-associated macrophages and/or G1 arrest
in tumor cells. European Journal Of Pharmacology. 746 pp. 115-125 (2015).
[160] Byrne, H., Cox, S. & Kelly, C. Macrophage-tumour interactions: in vivo
dynamics. Discrete Continuous Dynamical Systems-B. 4, 81 (2004).
[161] Pillis, L., Renee Fister, K., Gu, W., Collins, C., Daub, M., Gross, D.,
Moore, J. & Preskill, B. Mathematical model creation for cancer chemo-
immunotherapy. Computational And Mathematical Methods In Medicine. 10,
165-184 (2009).
162
[162] Kelleher, F. & O’Sullivan, H. Monocytes, Macrophages, and Osteoclasts in
Osteosarcoma. Journal Of Adolescent And Young Adult Oncology. 6, 396-405
(2017).
[163] Aras, S. & Zaidi, M. TAMeless traitors: macrophages in cancer progression
and metastasis. British Journal Of Cancer. 117, 1583-1591 (2017).
[164] Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and
activation of the immune system. Nature Reviews Immunology. 12, 180-190
(2012).
[165] Fisher, D., Appenheimer, M. & Evans, S. The two faces of IL-6 in the tumor
microenvironment. Seminars In Immunology. 26, 38-47 (2014).
[166] Whelan, J., Patterson, D., Perisoglou, M., Bielack, S., Marina, N., Smeland,
S. & Bernstein, M. The role of interferons in the treatment of osteosarcoma.
Pediatric Blood Cancer. 54, 350-354 (2010).
[167] Rovere-Querini, P., Capobianco, A., Scaffidi, P., Valentinis, B., Catalan-
otti, F., Giazzon, M., Dumitriu, I., Müller, S., Iannacone, M., Traversari,
C., Bianchi, M. & Manfredi, A. HMGB1 is an endogenous immune adjuvant
released by necrotic cells. EMBO Reports. 5, 825-830 (2004).
[168] Yang, J., Ma, Z., Wang, Y., Wang, Z., Tian, Y., Du, Y., Bian, W., Duan, Y.
& Liu, J. Necrosis of osteosarcoma cells induces the production and release of
high-mobility group box 1 protein. Experimental And Therapeutic Medicine.
15, 461-466 (2018).
[169] Kang, R., Zhang, Q., Zeh, H., Lotze, M. & Tang, D. HMGB1 in cancer:
Good, bad, or both?. Clinical Cancer Research. 19, 4046-4057 (2013).
[170] Ma, Y., Shurin, G., Peiyuan, Z. & Shurin, M. Dendritic cells in the cancer
microenvironment. Journal Of Cancer. 4, 36-44 (2013).
[171] Pahl, J., Kwappenberg, K., Varypataki, E., Santos, S., Kuijjer, M., Mo-
hamed, S., Wijnen, J., Tol, M., Cleton-Jansen, A., Egeler, R. & Others
Macrophages inhibit human osteosarcoma cell growth after activation with
the bacterial cell wall derivative liposomal muramyl tripeptide in combination
with interferon-. Journal Of Experimental Clinical Cancer Research. 33, 1-13
(2014).
[172] Jacobson, N., Szabo, S., Weber-Nordt, R., Zhong, Z., Schreiber, R., Darnell
Jr, J. & Murphy, K. Interleukin 12 signaling in T helper type 1 (Th1) cells
involves tyrosine phosphorylation of signal transducer and activator of tran-
scription (Stat) 3 and Stat4.. The Journal Of Experimental Medicine. 181,
1755-1762 (1995).
163
[173] Couper, K., Blount, D. & Riley, E. IL-10: the master regulator of immunity
to infection. The Journal Of Immunology. 180, 5771-5777 (2008).
[174] Oh, S. & Li, M. TGF-: guardian of T cell function. The Journal Of Immunol-
ogy. 191, 3973-3979 (2013).
[175] Lafont, V., Sanchez, F., Laprevotte, E., Michaud, H., Gros, L., Eliaou, J.
& Bonnefoy, N. Plasticity of T cells: Impact on the anti-tumor response.
Frontiers In Immunology. 5, 1-13 (2014).
[176] Henry, C., Ornelles, D., Mitchell, L., Brzoza-Lewis, K. & Hiltbold, E. IL-
12 produced by dendritic cells augments CD8+ T cell activation through the
production of the chemokines CCL1 and CCL17. The Journal Of Immunology.
181, 8576-8584 (2008).
[177] Li, L., Jay, S., Wang, Y., Wu, S. & Xiao, Z. IL-12 stimulates CTLs to secrete
exosomes capable of activating bystander CD8+ T cells. Scientific Reports. 7,
1-10 (2017).
[178] Dyson, K., Stover, B., Grippin, A., Mendez-Gomez, H., Lagmay, J., Mitchell,
D. & Sayour, E. Emerging trends in immunotherapy for pediatric sarcomas.
Journal Of Hematology And Oncology. 12, 1-10 (2019).
[179] Tsukumo, S. & Yasutomo, K. Regulation of CD8+ T cells and antitumor
immunity by Notch signaling. Frontiers In Immunology. 9 pp. 101 (2018).
[180] Durgeau, A., Virk, Y., Corgnac, S. & Mami-Chouaib, F. Recent advances
in targeting CD8 T-cell immunity for more effective cancer immunotherapy.
Frontiers In Immunology. 9 pp. 14 (2018).
[181] Folkman, J. & Hochberg, M. Self-regulation of growth in three dimensions.
The Journal Of Experimental Medicine. 138, 745-753 (1973).
[182] Enderling, H., Sunassee, E. & Caudell, J. Predicting patient-specific radio-
therapy responses in head and neck cancer to personalize radiation dose frac-
tionation. BioRxiv. pp. 630806 (2019).
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